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IMPORTANT COVARIATES
Xing Yuan, PhD
University of Pittsburgh, 2009
Meta-analysis can be broadly defined as the quantitative review and synthesis of the results
of related but independent studies into a single overall result. It is a statistical analysis that
combines or integrates the results of several independent clinical trials considered by the
analyst to be “combinable”. In many biomedical research areas, especially clinical trials in
oncology, researchers often use time to some event (or death) as the primary endpoint to
assess treatment effects. As the amount of survival analyses continues to increase, there is a
greater need to summarize a pool of studies into a coherent overview.
It is well established that in Cox proportional hazard models with censored survival data,
estimates of treatment effects with some important covariates omitted will be biased toward
zero. This is especially problematic in meta-analyses which combine estimates of parameters
from studies where different covariate adjustments are made. Presently, few constructive
solutions have been provided to address this issue. We propose a meta-analytic framework
for combining incomparable Cox models using both aggregated patient data (APD) and indi-
vidual patient data (IPD) structures. For APD, two meta-regression models (meta-ANOVA
and meta-polynomial models) with indicators of different covariates in Cox models are pro-
posed to adjust for the heterogeneity of treatment effects across studies. Both parametric
and nonparametric estimators for the pooled treatment effect and the heterogeneity vari-
ance are presented and compared. For IPD, we propose a hierarchical multiple imputation
method to handle the unique missing covariates problem when we combine individual data
from different studies for a meta-analysis, and results are compared with estimations from
the conventional multiple imputation method. We illustrate the advantages of our proposed
iv
analytic procedures over existing methodologies by simulation studies and real data analyses
using multiple breast cancer clinical trials.
The public health significance of our work is to provide practical guidance of designing
and implementing meta-analyses of incomparable Cox proportional hazard models for re-
searchers in the fields of clinical trials, medical research, and other health care areas. Such
guidance is important due to the emerging role of meta-analysis in assessing important public
health studies.
Keywords Meta-analysis, Survival analysis, Cox proportional hazard model, Heterogeneity,
Random effect model, Missing covariates.
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1.0 INTRODUCTION
Meta-analysis can be broadly defined as the quantitative review and synthesis of the results
of related but independent studies into a single overall result [57]. The term meta-analysis
was introduced by Gene Glass [20] in his 1976 presidential address to the American Edu-
cational Research Association as “the analysis of the results of statistical analyses for the
purpose of drawing general conclusions”. Since the introduction of meta-analysis, it has
been widely used in education, psychology, and biomedical research. The objectives of a
meta-analysis include increasing power to detect an overall treatment effect, estimation of
degree of benefits associated with a particular study treatment, assessment of the amount of
variability between studies, and identification of study characteristics associated with partic-
ularly effective treatment [52]. Although Glass coined this new term in 1976, the statistical
method of combining results of different studies has a long history. In early times, this often
took the form of several 푝-values being combined into a single value, using procedures such
as Fisher’s method [16]. Over the decades, there has been enormous number of papers using
meta-analyses to combine many types of effect sizes. The commonly used effect sizes fall
into one of the two families: the 푑 family (standardized difference between two groups) and
the 푟 family (correlation measures of effect size) [7].
1.1 META-ANALYZE SURVIVAL REGRESSION RESULTS
Methodologies of synthesizing the two types of effect sizes in meta-analysis have been inten-
sively studied and clearly documented in several major publications (see Hedges and Olkin
(1985) [26]; Rosenthal and Rubin (1986) [62]; Copper and Hedges (1994) [8]; Rosnow and
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Rosenthal (1996) [63]; Sutton et al. (2000) [71]; Lipsey and Wilson (2001) [45]; and Hunter
and Schmidt (2004) [35].). However, methods of synthesizing evidences from studies using
regression, especially in survival regression, have not yet been well studied.
In biomedical research areas, especially clinical trials in oncology, researchers often use
time to some event (or death) as the primary endpoint to assess treatment effects. The Cox
proportional hazard model [9], introduced by D. R. Cox, has been widely used in survival
analysis to accommodate both the effects of treatment and other important covariates. For
each subject, the hazard function with a set of covariates, 푥1, 푥2, . . . , 푥푝, can be decomposed
into two parts: one is the baseline hazard function involves time but not covariates, and one
that involves the covariates but not time. Hence,
ℎ(푡) = ℎ0(푡) exp(훽1푥1 + 훽2푥2 + . . .+ 훽푝푥푝). (1.1)
This semi-parametric model makes no assumptions about the nature or shape of the hazard
function, which makes Cox method more robust. Another advantage of using Cox propor-
tional hazard model is that it is relatively easy to incorporate different patterns of covariates,
such as interaction terms, higher-order variables or time-dependent covariates, in the model
to get more precise estimation of treatment effect.
As the amount of survival analyses done by scientists and investigators in universities,
government agencies, and other research institutes continues to increase, there is a greater
need to summarize a pool of studies into a coherent overview. Meta-analysis enhances the
researcher’s ability to combine seemingly contradictory results into a summary conclusion
of what all data has to say on the subjects. In addition, meta-analysis increases the power
of statistical analysis by combining results from separate (but similar) experiments, so that
it can provide information that would not otherwise be available. For example, a group of
clinical trials may all have positive treatment effect on survival that may be too small to be
significant by themselves, but when pooled can give convincing evidence of positive effect.
2
1.2 POTENTIAL PROBLEMS FROM COMBINING COX MODELS
The most interesting statistics from a Cox model, which can be used as effect sizes in the
meta-analysis, are the raw regression coefficients with their variances. When reporting the
treatment effect in a randomized controlled trial with a survival outcome, it is recommended
that the appropriate summary statistics are the log hazard ratio and its variance [56]. Sup-
pose in a meta-analysis combining 푘 Cox regression models, 푥1푖 is designated as the treatment
covariate in study 푖, 푖 = 1, 2, . . . , 푘. Then the raw regression coefficient of treatment variable
훽1푖 is the log hazard ratio while controlling for other covariates in the model. A na¨ıve ap-
proach is to take the simple average 훽¯1 but then we do not take into account that in different
studies, 훽1푖 have different precisions (SE) because of the variation in sample sizes and other
characteristics across the clinical trials. A better meta-analysis technique called fixed-effect
model can then be used, where a weighted average of all estimated coefficients is viewed as
the synthesized log hazard ratio when all trials combined together. Various weights have
been proposed but the most commonly used is the reciprocal of variance for each estimated
coefficient. However, a risk is that if the variance in one study is close to zero then the
combined result will be dominated only by that study. The meta-analysis model based on
the random effect approach assumes that studies may be heterogeneous, i.e., variations exist
between studies, and this variation is represented by the random effect with an unknown
variance.
One of the major problems when combining potential effect sizes from different Cox
regression models is the “incomparability” issue, that is, different studies may adjust for
different sets of covariates in the Cox models, so the coefficients of interest may have different
interpretations across the studies. If the groups are similar, except for the treatment under
study, this issue might not be problematic. More often than that, the subjects in the groups
have some additional characteristics that may affect their outcomes, such as demographic
variables or physiological variables. These variables may be used as covariates in the Cox
model in explaining the response variable. However, different trials have different protocols
and study designs, some of the significant variables are not observed for certain studies by
design or by happenstance. One way to deal with this problem is restricting all Cox models
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to have exactly the same set of covariates be included for the meta-analysis. Such a practice
may be a waste of useful information and Gail et al. (1984) [19] suggested that biases of
estimation are introduced due to omitted covariates. In particular, treatment effect estimates
with important covariates omitted will be biased toward zero (hazard ratio toward one) and
efficiency is lost for testing treatment effects.
In this dissertation, we will propose a meta-analytic framework for combining incompa-
rable Cox proportional hazard models caused by omitting important covariates. In the next
chapter, we give a summary of statistical methodologies commonly used for meta-analysis.
Also, three statistical techniques dealing with missing covariate data in the context of mod-
eling time-to-event type data are introduced and compared.
In Chapter 3, we present our proposed methods which account for the incomparability
issue of estimated coefficients in the meta-analysis framework. In Chapter 4, simulation
studies and data analyses using multiple breast cancer clinical trials provide that proposed
methods outperform the commonly used meta-analysis methods. Lastly, in Chapter 5, we
make recommendations and outline directions for further research.
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2.0 LITERATURE REVIEW
2.1 STATISTICAL METHODOLOGIES FOR META-ANALYSIS
Properly conducted meta-analyses are thought to represent among the highest level of evi-
dence addressing important biomedical issues. There are two types of meta-analysis method-
ologies based on the data availability. One is called aggregated patient data (APD) meta-
analysis. In many meta-analyses an attempt is made to obtain information for all relevant
clinical trials by collecting data summaries or APD from previous studies that have been
published or presented at professional meetings. A recent search of Medline by Lyman
and Kuderer (2005) [48] identified 1,595 reported meta-analyses related to cancer of which
1,519 (95.2%) were based on APD. The other type is called individual patient data (IPD)
meta-analysis. IPD meta-analysis has been described as the gold standard and yardstick
of systematic review [3]. Although it can be costly and time comsuming, there are many
advantages of using IPD meta-analysis: consistent analyses across studies, which is partic-
ularly important for survival data; the ability to easily perform subgroup analyses and to
use updated follow-up information; the consideration of covariates to examine adjusted dif-
ferences in treatment effectiveness across patients and trials; and the ability to assess the
appropriateness of the original analysis methods. Different statistical methodologies for both
APD and IPD meta-analysis are reviewed in the following sections.
2.1.1 APD Meta-Analysis
Although APD meta-analysis is not as desirable as IPD meta-analysis, it conceptually has the
same components including estimating the overall summary effect size and allowing one to as-
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sess heterogeneity. In certain circumstances, undertaking a large project involving obtaining
individual follow-up information may not be feasible owing to time or financial constraints.
Hence, using APD may be the only practical alternative. In other cases, researchers may
be able to obtain individual data but may wish to perform a APD meta-analysis first in a
preliminary analysis. Consequently, they can decide whether it is worthwhile to proceed with
the collection of individual data. The methodologies of APD meta-analysis are well devel-
oped and documented. Fixed-effect approaches include the use of inverse variance weighted
estimator [75], the Mantel-Haenszel (1959) procedures [49] and a method described by Peto
(1985) [78]. The most common random effect approach was described by DerSimonian and
Laird (1986) [13].
Suppose we have a series of 푘 studies, each comparing an experimental treatment to a
control with respect to a time to event outcome. If all of the studies are expected to share
a common treatment effect, or if we are interested in the average of the treatment effect
in the series of studies, it is natural to pool estimates across studies. In fixed-effect meta-
analyses, it is assumed that the true effect of treatment is the same in each study, or “fixed”.
The differences between study results are considered to be solely due to the play of chance.
Hence, the assumption of a fixed effect can be tested using a test of heterogeneity. Among
fixed-effect methods, the Mantel-Haenszel procedure is suitable for dichotomous outcomes
and Peto’s odds ratio method is an alternative to the Mantel-Haenszel method. Details
about these two methods can be found elsewhere [49, 78].
2.1.1.1 Inverse Variance Fixed-Effect Method The inverse variance method may
be used to pool either binary or continuous data. In general, the true effect size 휃푖 for study
푖, 푖 = 1, 2, . . . , 푘, could be the log odds ratio, log relative risk, risk difference, or difference in
means or standardized means. In the setting of APD meta-analysis for survival data, we may
only observe the log hazard ratio 휃푖 and its variance 휎
2
푖 for study 푖. The effect sizes are then
combined to give a pooled estimate for the true overall treatment effect, 휃, by calculating a
weighted average of the treatment effects from the individual trials:
휃ˆIV =
∑푘
푖=1푤푖휃푖∑푘
푖=1 푤푖
. (2.1)
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and the weights here are the reciprocals of the variances, that is,
푤푖 =
1
휎2푖
. (2.2)
The variance of 휃ˆIV is given by
var(휃ˆIV) =
1∑푘
푖=1 푤푖
. (2.3)
When the number of studies is large in the meta-analysis, 휃ˆIV is assumed to be normally
distributed with mean 휃 and variance as in equation (2.3). We can then test the null
hypothesis 퐻0 : 휃 = 0 by forming 푍 = 휃ˆIV/
√
var(휃ˆIV) and comparing it to a standard
normal distribution with significance level 훼 (Wald test). Additionally, an approximate 95%
confidence interval for 휃 is
(
휃ˆIV − 1.96
√
var(휃ˆIV), 휃ˆIV + 1.96
√
var(휃ˆIV)
)
.
If the number of studies in an APD meta-analysis is small, the assumption of normality
may not be appropriate. Follmann and Proscham (1999) [17] proposed a group permutation
method for hypothesis testing, where they permuted the treatment and control group labels
en masse within each trial. This provides a permutation reference distribution for the
estimate of treatment effect, which has better power and preserves the nominal Type I
error level better than a Wald test.
The classical measure of heterogeneity is Cochran’s 푄 statistic [6], which is calculated
as the weighted sum of squared differences between individual study effects and the pooled
estimated effect across all studies, with the weights in (2.2) being used. Hence, following the
notation of DerSimonian and Laird (1986) [13],
푄 =
푘∑
푖=1
푤푖(휃푖 − 휃ˆIV)2. (2.4)
Under the null hypothesis, 퐻0 : 휃1 = 휃2 = . . . = 휃푘, 푄 is distributed as a 휒
2 statistic
with (푘 − 1) degrees of freedom. The 푄 test has low power as a comprehensive test of
heterogeneity, especially when the number of studies is small [23]. Conversely, the test
arguably has excessive power when there are many studies, especially when those studies
are large [31]. Despite these drawbacks, the 푄 test is still very popular and used in many
meta-analyses.
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Intuitively, the larger studies which have smaller variances, are given more weights than
smaller studies, which have larger variances. Hence, the weights given in equation (2.2)
minimize the variability of the pooled treatment effect 휃ˆIV. However, a risk is that if one
very large study has a variance close to zero (although unlikely in real cases), the pooled
estimate will be dominated by that study. The meta-analysis model based on the random
effect approach provides something of a compromise assuming that studies are heterogeneous,
i.e., there is a random effect.
2.1.1.2 DerSimonian and Laird Random Effect Model In the fixed meta-analysis
models, 휃푖 is treated as an observation and the within-study variance 휎
2
푖 is treated as a fixed
number. In the random effect modeling approach, it is assumed that there exists a between-
study variation besides the variation within each study. And this between-study variation is
represented by the random effect 푎푖 with mean zero and unknown variance 휏
2. So the simple
random effect model is written as
휃푖 = 휃 + 푎푖 + 휀푖, (2.5)
where 휃푖 is the observed study-specific treatment effect, 휃 is the true overall treatment effect,
푎푖 is the random effect and 휀푖 is an error term with mean zero and known variance 휎
2
푖 .
The pooled estimate of the common treatment effect provided by DerSimonian and Laird
(1986) [13] is
휃ˆDL =
∑푘
푖=1푤
∗
푖 휃푖∑푘
푖=1 푤
∗
푖
, (2.6)
with variance
var(휃ˆDL) =
1∑푘
푖=1 푤
∗
푖
, (2.7)
where each study’s effect size is given weight
푤∗푖 =
1
휎2푖 + 휏
2
. (2.8)
We can also test 퐻0 : 휃 = 0 by forming 푍
′ = 휃ˆDL/
√
var(휃ˆDL) and comparing to a standard
normal distribution. The approximate 95% confidence interval for 휃 is
(
휃ˆDL−1.96
√
var(휃ˆDL),
휃ˆDL + 1.96
√
var(휃ˆDL)
)
.
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Thus, the heterogeneity variance 휏 2 is the key parameter in random effect meta-analysis.
If 휏 2 were known, the weighted average (2.6) would be unbiased with minimum variance
among all linear unbiased estimators following from the Gauss-Markov theorem. There are
mainly two methods estimating the variance of the random effect: maximum likelihood
estimation and quadratic method of moments estimation [11].
Maximum Likelihood Estimation
If we assume 푎푖 and 휀푖 follow normal distribution, (2.5) can be written as
휃푖 ∼ 풩 (휃, 휎2푖 + 휏 2), (2.9)
so that the log-likelihood function is
푙(휃, 휏 2) ∝ −1
2
푘∑
푖=1
[
ln(휎2푖 + 휏
2) +
(휃푖 − 휃)2
휎2푖 + 휏
2
]
. (2.10)
To use Newton-Raphson algorithm to get the maximum likelihood estimation (MLE),
we need the first and second derivatives with respect to 휃 and 휏 2:
∂푙
∂휃
=
푘∑
푖=1
휃푖 − 휃
휎2푖 + 휏
2
,
∂푙
∂휏 2
= −1
2
푘∑
푖=1
[
1
휎2푖 + 휏
2
− (휃푖 − 휃)
2
(휎2푖 + 휏
2)2
]
,
∂2푙
∂휃2
= −
푘∑
푖=1
1
휎2푖 + 휏
2
= 퐻11,
∂2푙
∂(휏 2)2
=
1
2
푘∑
푖=1
[
1
(휎2푖 + 휏
2)2
− 2(휃푖 − 휃)
2
(휎2푖 + 휏
2)3
]
= 퐻22,
∂2푙
∂휃∂휏 2
= −
푘∑
푖=1
[
휃푖 − 휃
(휎2푖 + 휏
2)2
]
= 퐻12 = 퐻21.
And the Hessian matrix for 푙(휃, 휏 2) is
H =
⎡⎣ 퐻11 퐻12
퐻21 퐻22
⎤⎦ .
As we can see, the second derivative of the log-likelihood function with respect to 휏 2, i.e.
퐻22, may be positive. This means the Newton-Raphson algorithm may fail if the starting
point is far from the maximum.
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The information matrix, which is the negative expected Hessian matrix of the log-
likelihood function, is given by
퓘 = −퐸(H) =
⎡⎣ ∑푘푖=1 1휎2푖 +휏2 0
0 1
2
∑푘
푖=1
1
(휎2푖 +휏
2)2
⎤⎦ .
Unlike the Hessian matrix, the information matrix, ℐ, is always positive definite and there-
fore, the Fisher Scoring (FS) algorithm is more reliable than the Newton-Raphson algorithm.
Since the information matrix is block-diagonal, the FS algorithm leads to separate maximiza-
tion over 휃 and 휏 2:
휃ˆ푠+1 = 휃ˆ푠 +
(
푘∑
푖=1
1
휎2푖 + 휏ˆ
2
푠
)−1 푘∑
푖=1
휃푖 − 휃ˆ푠
휎2푖 + 휏ˆ
2
푠
=
(
푘∑
푖=1
1
휎2푖 + 휏ˆ
2
푠
)−1 푘∑
푖=1
(
휃ˆ푠
휎2푖 + 휏ˆ
2
푠
+
휃푖 − 휃ˆ푠
휎2푖 + 휏ˆ
2
푠
)
=
(
푘∑
푖=1
1
휎2푖 + 휏ˆ
2
푠
)−1 푘∑
푖=1
휃푖
휎2푖 + 휏ˆ
2
푠
, (2.11)
휏ˆ 2푠+1 = 휏ˆ
2
푠 +
(
푘∑
푖=1
1
(휎2푖 + 휏ˆ
2
푠 )
2
)−1 푘∑
푖=1
(
(휃푖 − 휃ˆ푠)2
(휎2푖 + 휏ˆ
2
푠 )
2
− 1
휎2푖 + 휏ˆ
2
푠
)
=
(
푘∑
푖=1
1
(휎2푖 + 휏ˆ
2
푠 )
2
)−1 푘∑
푖=1
(
휏ˆ 2푠
(휎2푖 + 휏ˆ
2
푠 )
2
+
(휃푖 − 휃ˆ푠)2
(휎2푖 + 휏ˆ
2
푠 )
2
− 1
휎2푖 + 휏ˆ
2
푠
)
=
(
푘∑
푖=1
1
(휎2푖 + 휏ˆ
2
푠 )
2
)−1 푘∑
푖=1
(
(휃푖 − 휃ˆ푠)2 − 휎2푖
(휎2푖 + 휏ˆ
2
푠 )
2
)
, (2.12)
where 푠 is the iteration index and a good starting point of 휏ˆ 20 could be 0. We can see that
equation (2.11) takes the form of the weighted average (2.6).
Harville (1977) [24] preferred restricted maximum likelihood (REML) estimation to the
maximum likelihood estimation. The log-likelihood function of REML is
푙푅(휃, 휏
2) ∝ −1
2
{
푘∑
푖=1
[
ln(휎2푖 + 휏
2) +
(휃푖 − 휃)2
휎2푖 + 휏
2
]
+ ln
푘∑
푖=1
(휎2푖 + 휏
2)−1
}
. (2.13)
The FS algorithm of 휏 2 takes the form
휏ˆ 2푠+1 =
(
푘∑
푖=1
1
(휎2푖 + 휏ˆ
2
푠 )
2
)−1 푘∑
푖=1
(
(휃푖 − 휃ˆ푠)2 − 휎2푖
(휎2푖 + 휏ˆ
2
푠 )
2
)
+
1∑푘
푖=1 (휎
2
푖 + 휏
2
푠 )
−1 , (2.14)
with a good starting point, 휏ˆ 20 = 0.
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Quadratic Method of Moments Estimation
Under the quadratic method of moments estimation, the assumption of normality is relaxed.
This distribution-free property is very attractive especially when the number of study 푘 is
small. We have already constructed the weighted sum of squares of residuals 푄 as in (2.4).
To calculate the expected value 퐸(푄), Kacker (2004) [38] verified that
퐸(휃푖 − 휃IV) = 0,
퐸(휃푖 − 휃IV)2 = var(휃푖 − 휃IV)
= var(휃푖) + var(휃IV)− 2cov(휃푖, 휃IV)
= var(휃푖) +
∑푘
푖=1푤
2
푖 var(휃푖)
(
∑푘
푖=1 푤푖)
2
− 2푤푖var(휃푖)∑푘
푖=1 푤푖
.
So the expected value of 푄 is
퐸(푄) = 퐸
(
푘∑
푖=1
푤푖(휃푖 − 휃IV)2
)
=
푘∑
푖=1
푤푖var(휃푖) +
∑푘
푖=1푤
2
푖 var(휃푖)∑푘
푖=1푤푖
− 2
∑푘
푖=1 푤
2
푖 var(휃푖)∑푘
푖=1푤푖
=
푘∑
푖=1
푤푖var(휃푖)−
∑푘
푖=1푤
2
푖 var(휃푖)∑푘
푖=1 푤푖
=
푘∑
푖=1
푤푖(휎
2
푖 + 휏
2)−
∑푘
푖=1 푤
2
푖 (휎
2
푖 + 휏
2)∑푘
푖=1푤푖
= 휏 2
(
푘∑
푖=1
푤푖 −
∑푘
푖=1푤
2
푖∑푘
푖=1 푤푖
)
+
(
푘∑
푖=1
푤푖휎
2
푖 −
∑푘
푖=1 푤
2
푖 휎
2
푖∑푘
푖=1 푤푖
)
(2.15)
If we plug 휎2푖 = 푤
−1
푖 in equation (2.15) and equate the empirical sum 푄 to its expected
value, we have the following weighted method of moments estimate 휏ˆ 2푊푀푀
휏ˆ 2푊푀푀 =
푄− (푘 − 1)(∑푘
푖=1푤푖 −
∑푘
푖=1 푤
2
푖∑푘
푖=1 푤푖
) (2.16)
as derived by DerSimonian and Laird (1986) [13]. Here 푄 is the heterogeneity statistic and
the weights 푤푖’s are calculated as in the inverse variance method (2.2).
11
However, there is a general problem with estimation of variance components — the
estimates may be negative, e.g., when 푄 < 푘 − 1. Accordingly, we truncate the weighted
method of moments estimate as
휏˜ 2푊푀푀 = max(0, 휏ˆ
2
푊푀푀). (2.17)
The problem with this estimator is that it is slightly positively biased. This bias is often
observed for small between-study heterogeneity.
2.1.1.3 Meta-Regression In Section (2.1.1.1), Cochran’s 푄 statistic for testing the het-
erogeneity among results of 푘 studies was introduced. If there is a substantial heterogeneity
between the studies, we need to investigate whether the heterogeneity is related to specific
characteristics of the studies. In the context of meta-analysis, that can be done by including
covariates on the study level (which could “explain” differences between studies) into the
random effect model. Hence equation (2.5) becomes:
휃푖 = Z
′
푖휶+ 푎푖 + 휀푖, (2.18)
where 휃푖 is the observed study-specific treatment effect, Z푖 = (1, 푧1, 푧2, . . . , 푧푚)
′ is the
(1 + 푚) × 1 vector of covariates measured in study 푖 including the constant term, 휶 =
(훼0, 훼1, 훼2, . . . , 훼푚)
′ is the coefficient vector where the intercept term, 훼0, is interpreted as
the common treatment effect, 푎푖 is the random effect with unknown variance 휏
2 and 휀푖 is an
error term with mean zero and study-specific variance 휎2푖 .
The relation between 휃푖 and the “predictor” Z푖 could be modeled by a normal distribution
if the number of studies 푘 is large. We get the marginal approximate model
휃푖 ∼ 풩 (Z′푖휶, 휎2푖 + 휏 2). (2.19)
If 휏 2 is known, then we apply weighted least squares with
휶ˆ =
(
푘∑
푖=1
푤∗푖Z푖Z
′
푖
)−1( 푘∑
푖=1
푤∗푖Z푖휃푖
)
, (2.20)
where the weight, 푤∗푖 = (휎
2
푖 + 휏
2)−1, is as in the DerSimonian and Laird weighted estimate
(2.6).
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To get the MLE of 휏 2, we can easily generalize the FS algorithm by replacing 휃ˆ푠 with
Z′푖휶ˆ푠 in the recursive equation (2.12), where
휶ˆ푠 =
(
푘∑
푖=1
(휎2푖 + 휏ˆ
2
푠 )
−1Z푖Z′푖
)−1( 푘∑
푖=1
(휎2푖 + 휏ˆ
2
푠 )
−1Z푖휃푖
)
. (2.21)
The weighted method of moments estimator of 휏 2 has the form
휏ˆ 2푊푀푀 =
푄∗ − (푘 −푚)∑푘
푖=1 휎
−2
푖 − 푡푟
[(∑푘
푖=1 휎
−2
푖 Z푖Z
′
푖
)−1 (∑푘
푖=1 휎
−4
푖 Z푖Z
′
푖
)] , (2.22)
where
푄∗ =
푘∑
푖=1
휎−2푖 (휃푖 − Z′푖휶ˆ0)2, (2.23)
휶ˆ0 =
(
푘∑
푖=1
휎−2푖 Z푖Z
′
푖
)−1( 푘∑
푖=1
휎−2푖 Z푖휃푖
)
. (2.24)
Under the null hypothesis 퐻0 : 휏
2 = 0, we have
푄∗ ∼ 휒2(푘 −푚− 1), (2.25)
where 푚 is the number of covariates in the meta-regression model (2.18).
Meta-regression has become a standard model for assessing the potential impact of study-
level covariates [71]. Although this method is widely used in systematic review, there are
certain problems and limitations associated with this type of analysis: for example, the false-
positive rate of the resulting tests for the evidence of effect of covariates can be higher than
the nominal level because of the potential presence of heterogeneity [30] and innumerable
characteristics of different studies may be identified as potential cause of heterogeneity. It is
difficult to identify all of the covariates which, indeed, have influence on the treatment effect.
There is a great danger of over-fitting since the numbers of studies in meta-analyses are usu-
ally small. Consequently, meta-regression should be carefully designed and analyzed, since
the conclusions may be potentially misleading if results from meta-regression are interpreted
na¨ıvely.
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2.1.2 IPD Meta-Analysis
In Section (2.1.1.3), we considered only analyses of meta-regression at the aggregated meta-
analytic level. We did not consider covariates at the individual level. However, if such
information is available, the data should be analyzed by IPD meta-analysis methods. IPD
meta-analysis has been described as the gold standard and yardstick of systematic review [3].
This approach has several advantages over APD meta-analysis: consistent analyses across
studies, which is particularly important for survival data; ability of undertaking subgroup
analyses and using updated follow-up information; the consideration of covariates to examine
differences in treatment effectiveness across patients and trials; and the possibility of assess-
ing the appropriateness of original analysis methods. However, obtaining and analyzing IPD
can be both costly and time consuming.
There are two general approaches to IPD meta-analysis [70]. The first method called a
“one-stage analysis”, pools IPD from all studies together so that a single analysis can be
performed. This could be a “mega-trial” analysis, where distinctions between studies are
ignored and the data are analyzed as if they belong to a single trial, or by a stratified analysis
where the trial identities are included in the model. The second method called a “two-stage
analysis” includes studies in a meta-analysis which are analyzed separately with a consistent
modeling approach and then effect sizes and other summarized statistics are combined using
APD meta-analysis techniques. In the next section, we will mainly focus on one-stage IPD
meta-analysis.
2.1.2.1 One-Stage IPD Meta-Analysis Since we only focus on survival endpoints
in this dissertation, the general regression modeling approaches are skipped and we will
directly discuss the Cox proportional hazard model under the framework of one-stage IPD
meta-analysis. Although we can collect IPD from different trials and combine them to form
a “mega-trial”, this combined data set should not be analyzed with a simple Cox model
without further investigation. For example, factors that vary across studies, such as the
inclusion/exclusion criteria, patient characteristics, and therapeutic schemes or practice may
substantially influence the results. Thus, outcomes of the patients included in the same trial
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are likely to be less heterogeneous than those observed in patients included in different trials.
Such trial effects potentially lead to clustering, or dependence of outcomes at each trial. This
is sometimes referred as “clustered data”, where data from each trial define a cluster, and
some general methodologies used for multicenter clinical trials should be transposable to IPD
meta-analysis. However, differences between these two frameworks could lead to different
recommendations. First, multicenter trials may have more clusters but varying sample sizes
across trials whereas in IPD meta-analysis, each trial should have been adequately powered,
even if expected benefits may vary from trial to trial. Second, heterogeneity in multicenter
trials is often due to heterogeneity in baseline risks only, with fixed treatment effect across
trials. On the contrary, in meta-analysis literature, heterogeneity is usually intended as
heterogeneity in treatment effects across the trials, and modeling such heterogeneity becomes
a key issue [39].
Suppose we observe survival type of IPD from 푘 trials (clusters) and 푛푖 subjects per trial,
푖 = 1, 2, . . . , 푘. The total sample size of IPD meta-analysis, noted as 푁 , is thus
∑푘
푖=1 푛푖.
Let 푡0푖푗 be the latent failure time with 푐푖푗 denoting the censoring time for subject 푗 in trial
푖, 푗 = 1, 2, . . . , 푛푖. So the observed failure time is 푡푖푗 = min(푡
0
푖푗, 푐푖푗) and 훿푖푗 = 퐼{푡0푖푗 ⩽ 푐푖푗} is
the failure indicator. Also assume we observe a 푝−dimensional vector of covariates X푖푗 for
each subject. 푡푖푗 and 푐푖푗 are assumed to be independent conditionally on X푖푗 and identically
distributed with each trial. The (푡푖푗, 훿푖푗,X푖푗) are the observed variables. In the presence
of dependence induced by the trial effect, two distinct approaches are available: marginal
(or population-averaged) model and conditional (or trial-specific) model. The two strategies
differ in methods for estimation as well as interpretation. The virtues of each approach have
been extensively debated [22, 44, 51].
Marginal Cox Model
The fundamental difference between marginal model and conditional model is that in-
stead of modeling trial-specific effects, marginal model “averages out” the trial effects. The
marginal hazard of failure for subject 푗 in trial 푖 is
ℎ푖푗(푡∣X푖푗) = ℎ0(푡) exp(X′푖푗휷). (2.26)
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where 푖 = 1, 2, . . . , 푘 and 푗 = 1, 2, . . . , 푛푖. In this model, the baseline hazard ℎ0(푡) is not
specific to any trial. The average effect of treatment is between two randomly selected sub-
jects of the population in the whole meta-analysis: one treated and one untreated. Therefore,
there is no way to model the heterogeneity in treatment effect across trials. Nevertheless, the
“clustered” data structure is taken into account using a robust variance estimator [42, 41].
Conditional Cox Model
Generally, conditional models consist of fixed-effect Cox models, random effect Cox mod-
els (frailty models), and stratified Cox models. They share the general form which can be
written as
ℎ푖푗(푡∣X푖푗) = ℎ0푖(푡) exp(X′푖푗휷), (2.27)
where 푖 = 1, 2, . . . , 푘 and 푗 = 1, 2, . . . , 푛푖. Trial effects are incorporated in equation (2.27)
through the trial-specific baseline hazard function ℎ0푖(푡). The model is conditional in the
sense that the treatment effect is conditional on the trial-specific baseline hazard function.
Specifically, the hazard ratio for treatment comparing two subjects, e.g., one with treatment
and one with placebo, is from the same trial. A key feature of conditional model is the
decomposition of the trial-specific baseline hazard ℎ0푖(푡) into an arbitrary baseline hazard
rate ℎ0(푡) and an exponential term which models the multiplicative effect on this baseline
hazard.
In the fixed-effect Cox model, we assume trials act proportionally on the risk of failure
by adding additional terms to model (2.27). Without loss of generality, we arbitrarily choose
trial 1 as the reference trial, so that
ℎ푖푗(푡∣X푖푗) = ℎ0(푡) exp(훾푖 + X′푖푗휷) (2.28)
for 푖 = 1, 2, . . . , 푘, where 훾1 = 0. This model can be estimated by including trial indicator
variables in an unstratified Cox model. Model (2.28) assumes common treatment effect
adjusted for other covariates and requires estimation of (푘 − 1) + 푝 parameters, where 푝 is
the length of vector 휷.
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When the heterogeneity of treatment effects adjusted by other covariates exists across
trials, different trial-specific coefficients 휷푖 can be incorporated into conditional model (2.28),
leading to
ℎ푖푗(푡∣X푖푗) = ℎ0(푡) exp(훾푖 + X′푖푗휷푖), (2.29)
which requires the estimation of (푘 − 1) + 푘 × 푝 parameters.
When the number of trials is small relative to the sample size, the fixed-effect Cox model
is a very attractive approach, especially if the trial effect is of special interest. However, when
푘 → ∞, a large number of parameters must be estimated and the asymptotics may break
down. This major drawback of fixed-effect model can be very problematic in the extreme
cases where very large number of trials are being analyzed.
A better approach is the random effect Cox model or frailty model. Similar to the fixed-
effect Cox model, the frailty model assumes trials act proportionally on the baseline hazard
rate. However, instead of treating the trial effects as fixed parameters, the frailty model
treats them as a sample from a member of a family of probability distributions. In some
applications, it is more convenient to write model (2.27) as
ℎ푖푗(푡∣X푖푗) = ℎ0(푡)휉푖 exp(X′푖푗휷), (2.30)
where 휉푖 is the frailty for trial 푖, which represents the unmeasured factors affecting trial-
specific baseline hazard functions. Here we assume 휉푖’s are an independent sample from
some distribution with mean 1 and variance 휁20 . When 휁
2
0 = 0, model (2.30) reduces to a
simple Cox model, and trial effects are absent so that failures are independent within as well
as across trials. As 휁20 increases and nature picks a value of 휉푖 greater than 1 in trial 푖, then
subjects in that particular trial tend to fail at a faster rate than under a model where 휉푖 is
equal or smaller than 1.
The frailty model cannot generally be fitted by an extension of the standard partial likeli-
hood for Cox model. The likelihood may not have a closed form unless the frailty distribution
is carefully chosen. The most commonly used distribution in the literature is the one param-
eter gamma distribution introduced by Clayton (1978) [5]. This distribution yields a closed
form of likelihood which can be readily maximized. Other frailty distributions, which may or
may not result in closed-form likelihoods, include the positive stable distribution (Hougaard
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(1986a) [34]), the inverse Gaussian distribution (Hougaard (1986b) [33]), log-normal distri-
bution (McGilchrist (1993) [50]) and compound Poisson (Henderson (1999) [27]). All of these
models can be represented in equation (2.30) and use a single parameter to index the degree
of dependence. Thus, in contrast to the fixed-effect Cox model, the number of parameters
does not grow with the number of trials. In the gamma frailty distribution, for example,
only the variance 휁20 needs to be estimated in addition to the coefficient vector 휷.
Again, model (2.30) assumes common treatment effect. It can be modified to accom-
modate heterogeneity of treatment effects by adding trial-specific parameters 휷푖’s into the
model, so that
ℎ푖푗(푡∣X푖푗) = ℎ0(푡)휉푖 exp(X′푖푗휷푖). (2.31)
Equation (2.31) implies two model components. The first is the frailty term, 휉푖, modeling the
variation in baseline hazard. The second component is a model for the across-trial variation
in the treatment effect denoted by 휷푖. For the latter component, instead of fitting 휷푖 with a
fixed-effect strategy, we can denote 휷푖 as a sum of common effect 휷¯ and a mean zero random
effect 흎푖 = 휷푖 − 휷¯. Thus, the frailty model with random effects would have the form
ℎ푖푗(푡∣X푖푗) = ℎ0(푡)휉푖 exp(X′푖푗휷¯ + X′푖푗흎푖), (2.32)
where the distribution of 흎푖, 푖 = 1, 2, . . . , 푘, could be, for example, a log-gamma or a normal
distribution.
However, frailty models with random effects cannot be readily implemented with exist-
ing frailty model methodologies. Yamaguchi and Ohashi (1999) [77] presented a REML
algorithm to include random treatment effect in a log-normal frailty model as
ℎ푖푗(푡∣X푖푗) = ℎ0(푡) exp(훾푖 + X′푖푗휷¯ +푋 ′푖1푗휔푖1), (2.33)
where 훾푖 is the frailty term denoted as in (2.28), 푋푖1푗 is the first element of vector X푖푗
indicating the treatment group, which is of primary interest. The random effects 훾푖 and
휔푖1 are mutually independent and normally distributed with mean 0 and variance 휁
2
0 and
휁21 , respectively. In a Bayesian setting, the use of Markov chain Monte Carlo (MCMC)
computing allows a more flexible choice of distributions. Sargent (1998) [67] presented a
general framework through which random effects can be introduced into the Cox model
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using MCMC. This framework is using a Cox partial likelihood as the basis for a hierarchical
model, and allows very general random effect structures for the model parameters.
The third type of conditional model is the stratified Cox model. This model takes
the form of (2.27) with all 푘 baseline hazard functions ℎ0푖, 푖 = 1, 2, . . . , 푘, completely un-
specified. The stratified Cox model assumes trial-specified baseline hazard functions act
non-proportionally and it does not provide estimations of trial effects. However, the ease
of computing and the applicability across a wide variety of settings make the stratified Cox
model an appealing tool, especially when the trial effects are of no special interest. The
stratified Cox model can also fit trial-specific parameters into the model as
ℎ푖푗(푡∣X푖푗) = ℎ0푖(푡) exp(X′푖푗휷푖). (2.34)
However, this formulation is equivalent to fitting a separate model for each trial, and it
does not combine information as is done in a meta-analysis. Therefore, this case will not be
considered in this dissertation.
So far, under the one-stage IPD meta-analysis framework, we have compared four models
presented above, namely, the marginal Cox model, the fixed-effect Cox model, the random
effect Cox model or so-called frailty model, and the stratified Cox model. The last three
models share the same general form of conditional Cox model.
2.1.2.2 Two-Stage IPD Meta-Analysis The two-stage IPD meta-analysis follows the
same statistical methodology of APD meta-analysis, and it is currently the most commonly
used method of analyzing IPD. It is conceptually straightforward and is familiar to most
researchers. For survival data, a common Cox model with treatment variable and the same
set of other adjust covariates is applied for each study and then log-hazard ratios of treatment
effect are collected to form a pooled estimate. From a purely statistical perspective, it
may not be worthwhile to perform a two-stage IPD meta-analysis unless the appropriate
summary results are not available. However, there are many benefits to collecting IPD,
including data checking, data updating for longer term follow-up of participants, dealing
with missing data, and checking the consistency of original analysis methods. For these
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reasons, results from two-stage IPD meta-analyses and equivalent APD meta-analyses can
be very different [37, 72].
2.2 STATISTICAL METHODOLOGIES FOR MISSING COVARIATES IN
SURVIVAL ANALYSIS
In the previous section, we explained the advantages of IPD meta-analysis as a major im-
provement over APD meta-analysis. However, problems of missing covariates complicate
IPD meta-analysis, and especially for IPD meta-analysis using Cox regression models which
require full covariate information. A na¨ıve approach to solve missing covariates problem is to
analyze only the subjects with complete observations. This so-called complete case analysis
may not only reduce precision because only part of the data is used but also may produce
biased results when the missing data are not missing completely at random (MCAR). More
sophisticated approaches for handling missing covariates in Cox model have been proposed
for a single study. However, not only the frequency of missing data but also the missingness
process may vary across studies from which individual data are pooled [40]. Thus different
approaches of handling missing covariates for a single study may, therefore, not be directly
implemented for IPD meta-analysis.
Statistical methodologies developed to estimate parameters of Cox model with missing
covariates have a large bibliography, including several reviews and textbooks. We will re-
view three different types of approaches: multiple imputation, likelihood-based methods and
weighted estimating equation methods.
2.2.1 Multiple Imputation Method
Since its introduction 30 years ago by Rubin (1978) [64], multiple imputation (MI) has
become an important and influential approach for dealing with the statistical analysis of
missing data. The practice of filling in missing data with imputed plausible values has long
been reviewed as an attractive approach because it can “lull the user into the pleasure state
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of believing that the data are complete after all” [12]. As a result, standard statistical
procedures for complete data can be directly implemented.
For survival analysis, Paik and Tsai (1997) [55] proposed a single imputation method for
handling missing covariates in using Cox model under missing at random (MAR) mechanism.
In their paper, they proposed an estimator that is the solution of the approximated partial
likelihood equation obtained by replacing the missing covariates with the expectations of
observed covariates from the same risk set. Therefore, information on missing covariates
can be recovered from the observed covariates with proper conditioning. This estimator
is asymptotically normal and relatively efficient than previous methods under restricted
conditions. For one, it works best when the missing covariates are categorical with small
number of categories.
However, single imputation cannot reflect the sampling variability under one model for
nonresponse about the correct model for nonresponse. MI can be applied to salvage such
deficiency. The key idea of the MI procedure is to replace each missing value with a set of
푀 plausible values. Each value is a Bayesian draw from the conditional distribution of the
missing observations given the observed data. MI is most straightforward to use under MAR
but it is quite possible to apply it under missing not at random (MNAR) settings.
MI involves three distinct tasks [65]:
1. The missing values are filled in 푀 times to generate 푀 complete data sets.
2. The 푀 complete data sets are analyzed by using standard procedures.
3. The results from the 푀 analyses are combined into a single inference.
Paik (1997) [54] implemented a bootstrap-like MI technique proposed by Rubin and
Schenker (1986) [66] to estimate Cox model with missing covariates. In her technique,
called Approximate Bayesian Bootstrap (ABB), she first sampled with replacement from
the non-missing observations, then drew imputes from this bootstrap sample. This method
is based on the assumption that non-missing observations are all categorical. If not, we
need to employ histogram smoothing technique as suggested by Paik and Tsai (1997) [55],
in which each continuous covariate is categorized into appropriately chosen neighborhoods.
This smoothing technique, however, may introduce bias.
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The limitations of Paik’s MI are obvious and it can not impute multiple missing covariates
together with a multivariate fashion. Schafer (1997) [68], in his book, presented iterative
algorithms for simulating MI of missing categorical, continuous or mixed type of covariates
under multivariate models. The multiple imputation algorithm for MIX (estimation/multiple
imputation for mixed categorical and continuous data) in his book is based on the general
location model under MAR proposed by Olkin and Tate (1961) [53], and multiple imputations
are generated based on two concepts: one is the likelihood-based inference with missing data
using EM algorithm; the other one is the data augmentation method which uses a Markov
Chain Monte Carlo (MCMC) technique. The algorithms from this book are computationally
intensive but fortunately they are implemented in the package MIX for software R, which is
developed by Schafer (1997) [68] and can be downloaded from CRAN.
2.2.2 Direct Likelihood-Based Method
The Cox model assumes that the hazard function for failure time 푇 , conditional on the
covariates X푖, is of the form
lim
Δ푡→0
푃 (푡 ⩽ 푇 ⩽ 푡+ Δ푡)
Δ푡
= ℎ푖(푡∣X푖) = ℎ0(푡) exp(X′푖휷), 푖 = 1, 2, . . . , 푛, (2.35)
where X푖 is a 푝-dimensional vector of categorical or continuous covariates, ℎ0(푡) is an un-
specified baseline hazard function.
Generally, let 푇 0 be the latent failure time with 퐶 denoting the censoring time. So the
observed failure time is 푇 = min(푇 0, 퐶) and Δ = 퐼{푇 0 ⩽ 퐶} is the failure indicator. In the
case of non-informative censoring, the probability distribution for (푡푖, 훿푖∣X푖) conditional on
the covariates is given by
푃 (푡푖, 훿푖∣X푖,휷) ∝ 푃 (푡푖∣X푖,휷)훿푖푆(푡푖∣X푖,휷)1−훿푖
= ℎ푖(푡푖∣X푖,휷)훿푖푆(푡푖∣X푖,휷)
= [ℎ0(푡푖) exp(X
′
푖휷)]
훿푖 exp (− exp(X′푖휷)퐻0(푡푖)) , (2.36)
where 푆(푡∣X) = 푃 (푇 > 푡∣X) is the survival function for 푇 and 퐻0(푡) =
∫ 푡
0
ℎ0(푢)푑푢 is the
cumulative baseline hazard function.
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Thus, the log-likelihood for subject 푖 can be written as
푙(휷∣푡푖, 훿푖,X푖) = 훿푖 (log ℎ0(푡푖) + X′푖휷)− exp(X′푖휷)퐻0(푡푖). (2.37)
The parameters vector, 휷, can be estimated by maximizing function (2.37). Unfortu-
nately, this log-likelihood contains nuisance parameter ℎ0(푡) and 퐻0(푡). To avoid estimating
these parameters, a consistent estimator of 휷 can be obtained by maximizing the partial
likelihood (PL) presented by Cox (1975) [10], which in the absence of ties can be written as
퐿(휷∣푡푖, 훿푖,X푖) =
푛∏
푖=1
[
exp(X′푖휷)∑푛
푗=1 퐼푡푗⩾푡푖 exp(X
′
푖휷)
]훿푖
. (2.38)
Equating the partial likelihood score function to zero as the equation below yields the esti-
mator of 휷,
uPL(휷) =
∂ log퐿(휷∣푡푖, 훿푖,X푖)
∂휷
= 0. (2.39)
This estimator has been shown to be consistent and asymptotically normal (Andersen and
Gill (1982) [1]; Tsiatis (1981) [73]) and semi-parametrically efficient (Begun et al. (1983) [2]).
When some of the covariates are subject to missingness, we can write X푖 = (X
표푏푠
푖 ,X
푚푖푠
푖 ).
Prentice (1982) [58] suggested using 퐸(exp(X′푖휷)∣푇 ⩽ 푡,X푖 = X표푏푠푖 ) to replace exp(X′푖휷) in
the partial likelihood function (2.38). However, this conditional expectation is not indepen-
dent of the unknown baseline hazard function ℎ0(푡) so that it ruins the advantages of partial
likelihood. Zhou and Pepe (1995) [79] overcame this difficulty by using an estimated partial
likelihood (EPL), in which an estimated exponential term ˆexp(X′푖휷) is expressed as a sum
of exp(X′푖휷) (when covariates are complete) and a surrogate variable (when covariates are
missing). Later ˆexp(X′푖휷) is plugged in partial likelihood function (2.38) to get the estimator
of 휷. The EPL method can yield more efficient estimates than maximum partial likelihood
estimates based on complete-case analysis, but additional surrogate variables require strict
assumptions to be satisfied.
Alternatively, the information contained in the survival time (푡푖, 훿푖) can be represented
by the counting process {푁푖(푡), 푌푖(푡) : 푡 ⩽ 0}, where 푁푖(푡) = 퐼{푡푖⩽푡,훿푖=1} and 푌푖(푡) = 퐼{푡푖⩾푡} so
that
∑
푁푖(푡) is the number of death at or before time 푡 and
∑
푌푖(푡) is the risk set at time
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푡, respectively. Thus, the score function can be written as a stochastic integral in counting
process notation as
uPL(휷) =
푛∑
푖=1
∫ ∞
0
[
X푖 − X¯(휷, 푢)
]
푑푁푖(푢), (2.40)
where
X¯(휷, 푡) =
∑푛
푗=1 X푗푌푗(푡) exp(X
′
푗휷)∑푛
푗=1 푌푗(푡) exp(X
′
푗휷)
. (2.41)
That is, X¯(휷, 푡) is the average of X푖 over the risk set
∑
푌푖(푡), using an “exponentially
weighted” form of sampling.
Lin and Ying (1993) [43] introduced an approximate partial likelihood (APL) score func-
tion to estimate Cox model with missing covariates. This approach modified the partial
likelihood score function (2.40) by replacing the whole term within the integral with a
complete-case estimate. This estimator depends critically on the MCAR assumption and
sometimes is less efficient than analysis of complete cases.
Lipsitz and Ibrahim (1998) [46] developed a likelihood-based method to estimate the
parameters of Cox model when there are only categorical missing covariates. Under MAR, a
consistent estimate of 휷 can be obtained by letting the conditional expectation of the whole
score function (2.40) given observed data equal to 0 and solving for 휷ˆ as
u∗PL(휷) = 퐸[uPL(휷)∣observed data] = 0. (2.42)
Herring and Ibrahim (2001) [28] extended the methods proposed by Lipsitz and Ibrahim
(1998) [46] by using the Monte Carlo EM algorithm methods to estimate the parameters
of Cox model when missing covariates are categorical, continuous or mixed. This proposed
methodology is very general, which allows any type of missing covariates and works under
MAR, but the computation is quite intensive.
2.2.3 Weighted Estimating Equation Method
The methods that we have reviewed so far for accommodating missing covariates have all
involved, directly or indirectly, integration over the distribution of the missing data. For ex-
ample, this is done directly in constructing the likelihood and indirectly when using multiple
imputation. All such methods require assumptions to be made about the distribution, often
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in the form of its conditional distribution given the observed data, so that the results can
be very sensitive to these assumptions. An alternative method, called a weighted estimating
equation (WEE) based on the inverse probability weighting idea of Horvitz and Thompson
(1952) [32], is very robust to the distribution of unobserved data. With WEE, the contri-
bution to the estimating equation from a complete observation is weighted by 휋, the inverse
probability that the covariate is observed. However, this method may generate inefficient
estimators since in its basic form only the information of complete data is used.
Robins et al. (1994) [61] and Robins and Rotnitzky (1995) [60] developed a class of
estimators based on inverse-probability WEEs in a regression setting when data are MAR.
Lipsitz et al. (1999) [47] developed WEE methods, which are almost identical to the maxi-
mum likelihood estimating equations, for generalized linear models with missing categorical
and continuous covariates. As such, they extended Monte Carlo EM algorithm to a Monte
Carlo WEE to solve these weighted estimating equations. Following their notation, let 푦푖 be
the outcome variable, X푖 be a 푝-dimensional vector of completely observed covariates, and
covariates 푧푖 be missing for some subjects, 푖 = 1, 2, . . . , 푛. Additionally, an indicator variable
표푖 is defined, which equals to 1 if 푧푖 is observed and 0 if 푧푖 is missing. Thus, the distribution
of 표푖 given (푦푖,X푖, 푧푖) is a Bernoulli with probability 휋푖 = 푃 (표푖 = 1∣푦푖,X푖, 푧푖). If we write
u푖(휷∣푦푖,X푖, 푧푖) = ∂ log푃 (푦푖∣X푖, 푧푖,휷)
∂휷
, (2.43)
then the score function of WEE is
uWEE(휷) =
푛∑
푖=1
{
표푖
휋푖
u푖(휷∣푦푖,X푖, 푧푖) + (1− 표푖
휋푖
)퐸푧푖∣푦푖,X푖 [u푖(휷∣푦푖,X푖, 푧푖)]
}
. (2.44)
If in equation (2.44), 표푖/휋푖 is replaced by 표푖, this estimation equation becomes maxi-
mum likelihood score function and thus the solution will be exactly MLE. So one can use
a weighted-type EM algorithm to solve uWEE = 0. The WEEs will produce consistent esti-
mates if 휋푖 is correctly specified or the score vector for the missing data given the observed
data is correctly specified, but not necessarily both [36]. This is what Robins and others
often called double robustness.
In Robins et al. (1994) [61], they discussed the idea of adding an augmentation term to
a simple WEE under MAR. Based on this idea, Wang and Chen (2001) [74] proposed an
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augmented inverse probability weighted (AIPW) estimator for Cox model with missing cat-
egorical covariates, which includes terms that depend on the unknown cumulative baseline
hazard function 퐻0(푡) and the conditional distribution of missing covariates given observed
data. They imposed a parametric model 푃 (푧푖∣X푖,휶) for this conditional distribution and
suggested an EM algorithm to estimate regression coefficients 휷, as well as nuisance param-
eters 퐻0(푡) and 휶. This AIPW estimator holds the double robustness property. However,
the EM algorithm may not be feasible with a complex conditional distribution 푃 (푧푖∣X푖,휶).
Qi et al. (2005) [59] improved Wang and Chen’s AIPW estimator in two ways: they
proposed a generalized nonparametric method to estimate selection probability 휋푖; they also
proposed kernel-assisted fully augmented weighted estimators (FAWE) that, unlike Wang
and Cheng’s methods, do not put a parametric restriction on the association between missing
covariates and the observed covariates. In this method, nonparametric kernel smoothing
techniques are adopted to estimate conditional expectations that depends on the cumulative
baseline hazard function 퐻0(푡) and conditional distribution of the missing covariates given
the observed covariates.
The WEE method is more robust than likelihood-based method and it is more flexible in
specifying the parametric conditional distribution of missing covariates. However, if multiple
covariates are subject to missingness, i.e., Z푖 is a vector instead of an univariate variable 푧푖,
WEE performs best when all elements of Z푖 are observed or unobserved for 푖, thus the selec-
tion probability 휋푖 can be easily and correctly modeled. On the other hand, likelihood-based
method can easily handle more than one missing covariates with any pattern of missingness,
but it is theoretically complicated.
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3.0 PROPOSED METHODOLOGIES
As mentioned in the chapter of introduction, the major problem for combining different Cox
proportional hazard models to perform a meta-analysis is that estimates of parameters from
different Cox models where adjustment has been made for different subsets of covariates are
not comparable. As presented in the chapter of literature review, most of the meta-analysts
simply ignore the fact that it is inappropriate to combine effect sizes adjusted by different
covariates across studies, or some researchers found this problem (Chastang et al. (1988) [4],
Ford et al. (1995) [18], and Hauck et al. (1998) [25]) but did not provide any constructive
solution. Thus, in our proposed methods, we want to tackle this problem under both APD
and IPD meta-analysis frameworks.
3.1 LINEAR META-REGRESSION MODELS USING APD
The majority of meta-analyses often attempt to obtain data by collecting summaries or
APD from published studies, so we would look into the issues under the APD meta-analysis
framework first. Since we only observe effect sizes and summarized model information from
different studies, it is challenging to combine estimates of treatment effects where adjustment
has been made for different subsets of covariates. It appears that many statisticians are aware
that estimates of treatment effects may be biased in non-linear models if one fails to adjust
on prognostic variables even when the variables are perfectly balanced across treatment
groups using randomization. At first glance this statement seems counterintuitive because
no such bias would occur from omitting perfectly balanced prognostic variables in the more
familiar linear regression model, even thought some efficiency would be lost in estimating
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the treatment effect [19]. To better understand this issue, we need to investigate effects of
misspecification of Cox model by omitting important covariates in survival analysis.
3.1.1 Effects of Omitting Covariates in Cox Model for Survival Data
Suppose we observe survival time 푡푗 for each subject in a randomized clinical trial, 푗 =
1, 2, . . . , 푛. Let 푥1푗 be the indicator variable (with value 1 or −1) denoting treatment as-
signment and 푥2푗 be a baseline measure of some important covariate which can be assumed
related to 푡푗. The conclusions can be readily generalized to more complex cases. A standard
Cox proportional hazard model with both treatment indicator and the baseline covariate, is
given by model 1:
ℎ푗(푡∣푥1푗, 푥2푗) = ℎ0(푡) exp(훽1푥1푗 + 훽2푥2푗), (3.1)
where ℎ0(푡) is an unknown baseline hazard with integral 퐻0(푡).
And we also consider model 2, where covariate 푥2푗 has been dropped:
ℎ푗(푡∣푥1푗) = ℎ0(푡) exp(훽∗1푥1푗). (3.2)
In model 1 (3.1) 푥2푗 is a scalar. But multivariate extensions are straightforward by
denoting vector X2푗, and notation Ω is used for the covariance matrix of X2푗. Gail et al.
(1984) [19] provided an approximated estimation of the bias between 훽∗1 and 훽1 as
훿 = 훽∗1 − 훽1 ≈
1
4
휷′2Ω휷2 {푅(훽1)−푅(−훽1)} (3.3)
for vector X2푗, where
푅(휂) = 2휙′(휂)/휙(휂) + 1, (3.4)
휙(휂) = 퐸[퐻0(푡)∣휂]. (3.5)
The bias function (3.3) illustrates how the bias may be approximated and shows that 훽∗1
is generally biased unless 훽1 = 0 or 휷2 = 0. Additionally, longer length of the vector 휷2
indicates larger 훿, which means omitting more important covariates would increase the bias.
From the suggestion of normal linear model, the motivation for including covariates
is twofold. Besides decreasing the bias, we could expect a reduction of variance and hence
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increasing the precision of estimation of treatment effect. If we consider a simpler model that
the response is now a non-censored survival time from a particular exponential distribution,
namely,
푡푗 ∼ EXP(휆푗), (3.6)
where 휆푗 = exp(훽1푥1푗 + 훽2푥2푗) and 1/휆푗 is the mean of exponential distribution. Ford et al.
(1995) [18] showed that the variance of 훽ˆ1 under model 1 (3.1) can be approximated by
var(훽ˆ1) ≈ (1/
∑
푥21푗)/{1− [corr(푋1, 푋2)]2}, (3.7)
where corr(푋1, 푋2) is the sample correlation between 푥1푗’s and 푥2푗’s.
Under model 2 (3.2), the variance of 훽ˆ∗1 can be approximated by
var(훽ˆ∗1) ≈ (1/
∑
푥21푗). (3.8)
It is clear that the inclusion of covariate 푥2푗 can increase the variance since [corr(푋1, 푋2)]
2
is always non-negative. However, in a randomized clinical trial, corr(푋1, 푋2) will be close
to zero with high probability and hence the influence of adding covariates on variance of
treatment effect is likely to be trivial.
To demonstrate the bias of estimated treatment effects by omitted covariates with simu-
lation for censored exponential survival data, we generated a simulated data with a sample
of 800 patients using a Cox proportional hazard model given by
ℎ푗(푡) = ℎ0(푡) exp(훽1푥1푗 + 훽2푥2푗 + 훽3푥3푗 + 훽4푥4푗 + 훽5푥5푗), (3.9)
where the baseline failure time is generated from an exponential distribution with parameter
휆0 = 0.1. The covariates 푋1 and 푋4 are categorical variables and 푋2, 푋3 and 푋5 are
continuous variables. To simulate data similar to that observed in a breast cancer clinical
trial, we generated 푋1 from a Bernoulli distribution with 푝 = 0.5 to represent a treatment
indicator, 푋2 as a covariate of centered age from a normal distribution with mean 0 and
variance 100 and 푋3 as a covariate of tumor size generated from a 휒
2 distribution with 3
degrees of freedom. 푋4 is a Bernoulli variable with 푝 = 0.6, representing an indicator of
estrogen receptor positivity and 푋5 stands for number of lymph nodes involved with the
breast cancer, which was generated using an exponential distribution with rate 1/3 and
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rounded up to integers but was modified so that negative nodal status (푋5 = 0) would occur
in roughly 60% of the patients. To generate the survival times, the coefficients associateed
with 푋1-푋5 were set to
휷 = (훽1, 훽2, 훽3, 훽4, 훽5)
′ = (−0.2,−0.1, 0.1,−0.15, 0.7)′
based on values similar to those observed in breast cancer patients. Finally, the survival
times were randomly censored with probability 0.1.
We define five different models, each of which includes the treatment indicator 푋1. The
first model omits all other covariates. The second one omits all but one of the other covari-
ates. In Models 3-5, we continue to randomly add covariates one at a time so that Model 5
is correctly specified. Specifically, covariates included in the Cox models are
Model 1: 푋1,
Model 2: 푋1 +푋푎,
Model 3: 푋1 +푋푎 +푋푏,
Model 4: 푋1 +푋푎 +푋푏 +푋푐,
Model 5: 푋1 +푋2 +푋3 +푋4 +푋5,
where indices 푎, 푏 and 푐 are randomly chosen without replacement from {2, 3, 4, 5} so that
푎 ∕= 푏 ∕= 푐. Each simulated survival data was fitted with all five models and the estimated
treatment effects were recorded.
Figure 3.1 compares the estimated treatment effects 훽ˆ1’s from different Cox models with
all possible model specifications with 200 simulations. When models only have 푋1, they
yield the largest bias, whereas adding more covariates into the Cox model incrementally
decreases the bias, so that the realizations of model with all of the five covariates have a
median treatment effect almost identical to the true value −0.2. Hence we illustrate that for
Cox models with censored data, estimates of treatment effect with other covariates omitted
will be biased toward zero (hazard ratio toward to one), and the more the omitted covariates,
the larger the bias.
Figure 3.2 confirms the comparison between equation (3.7) and equation (3.8) that in-
cluding more covariates into Cox model could slightly increase the variance of treatment
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Figure 3.1: Estimated treatment effects from Cox proportional hazard models with different
numbers of covariates.
The 푥-axis indicates the number of covariates in different Cox models with possible misspecification. Treat-
ment indicator 푋1 is included in all the models. Other covariates 푋2, . . . , 푋5 are randomly selected into each
model according to the pre-specified number of covariates. For each model, there are 200 estimated 훽ˆ1s and
the dot stands for the median value. −0.2 is the true coefficient of treatment indicator.
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Figure 3.2: Standard errors of estimated treatment effects from Cox proportional hazard
models with different numbers of covariates.
The 푥-axis indicates the number of covariates in different Cox models with possible misspecification. Treat-
ment indicator 푋1 is always in all the models. Other covariates 푋2, . . . , 푋5 are randomly selected into each
model according to the pre-specified number of covariates. For each model, there are 200 standard errors
se(훽ˆ1) and the blue dot stands for the median value.
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effect estimation. However, the differences are negligibly small. From this simulation, the
difference of median standard errors between Model 1 and Model 5 is as small as 0.001.
3.1.2 Proposed Meta-Regression Models
Generally speaking, the basic principle of any research synthesis or meta-analysis is only
including related studies with similar study designs and focusing on the same research topic.
Otherwise, there exists the “Apples-and-Oranges” problem that Gene Glass talked in his
unpublished paper [21], in which he stated that the repeated criticism of meta-analysis was
that it was meaningless because it “mixed apples and oranges”. Obviously, there are a
lot sources of heterogeneity in treatment effects. Different clinical trials may use different
treatment protocols and have different study designs. Additionally, patients have baseline
covariates such as demographic variables or clinical or pathologic variables which may vary
substantially across studies, which may also affect their outcomes. In addition, there is
selection bias, publication bias, data irregularities and other debatable fundamental issues
with meta-analysis. These problems can generally be avoided if a few basic principles are
observed, such as a prior definition of inclusion criteria for studies and a comprehensive trial
search strategy. Similar to issues regarding the design of clinical trials, meta-analyses need
to be carefully planned with detailed written protocols being prepared in advance. We do
not address topics of the selection process or publication bias associated with meta-analyses
in this dissertation, but rather assume all studies share certain common characteristics and
that a “full” Cox model is globally best for all studies. Here the “full” Cox model is chosen
from one or more studies where all important covariates are measured and included, and
designate other studies as having some covariates omitted.
We propose two meta-regression models: a meta-ANOVA model and a meta-polynomial
model. These two models share the same general form,
휃푖 = Z
′
푖휶+ 푎푖 + 휀푖, 퐸(휃푖) = Z
′
푖휶, var(휃푖) = 휎
2
푖 + 휏
2, (3.10)
where 휃푖 is the observed study-specific treatment effect, Z푖 = (1, 푧1, 푧2, . . . , 푧푚)
′ is the (1 +
푚)×1 vector of covariates measured in study 푖 including the constant term, 푎푖 is the random
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effect with mean zero and unknown variance 휏 2, and 휀푖 is an error term with mean zero and
study-specific variance 휎2푖 .
Suppose we have 푘 studies included in a meta-analysis where we wish to potentially
adjust for up to 퐿 covariates via Cox regression models. Among the 퐿 covariates, 푋1 will be
designated as the treatment indicator and is included in all studies. However, some studies
may not have all of the other 퐿−1 covariates. In an APD meta-analysis, each study 푖 provides
a value of 훽ˆ푖1 (denoted as 휃푖) and var(훽ˆ푖1) (denoted as 휎
2
푖 ). Moreover, we can observe other
model information such as how many covariates are included in the Cox models and which
covariates are included.
Meta-ANOVA Model
Based on the Cox model information for each study 푖, we can create 퐿 indicators {푧푖푙} =
{퐼{푋푙 is included in study 푖}, 푙 = 1, 2, . . . , 퐿}. The indicator matrix Z = (푧푖푙)푘×퐿 can be written as
Z =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
1 푧12 푧13 . . . 푧1퐿
1 푧22 푧23 . . . 푧2퐿
1 푧32 푧33 . . . 푧3퐿
...
...
...
...
...
1 푧푘2 푧푘3 . . . 푧푘퐿
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
, (3.11)
and each row of Z is the vector Z푖 for study 푖.
Thus, the meta-ANOVA model can be written as
휃푖 = 훼0 + 훼1푧푖2 + 훼2푧푖3 + . . .+ 훼퐿−1푧푖퐿 + 푎푖 + 휀푖, (3.12)
where the intercept term 훼0 is the common treatment effect since treatment variable 푋1 is
always in the models, and 훼푙−1 is the incremental effect when covariate 푋푙 is included in the
Cox model, 푙 = 2, 3, . . . , 퐿.
Assuming that only the 휃푖s from the models with a full set of covariates are not biased,
our proposed estimator for the pooled treatment effect based on the meta-ANOVA model
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is the sum of the estimated common treatment effect 훼ˆ0 and the offsets due to addition of
covariates 푋2, 푋3, . . . , 푋퐿:
휃ˆM-A = 훼ˆ0 + 훼ˆ1 + 훼ˆ2 + . . .+ 훼ˆ퐿−1
= [ 1 1 1 . . . 1 ]× 휶ˆ.
= 1′퐿 × 휶ˆ. (3.13)
The variance of 휃ˆM-A is given by
var(휃ˆM-A) = 1
′
퐿var(휶ˆ)1퐿. (3.14)
Meta-polynomial Model
It is well established that for Cox proportional hazard models, the more important co-
variates omitted, the larger the bias in treatment effect estimation [25]. In Figure 3.1, we
observe a clear linear relationship between the estimated treatment effects 휃푖s and the num-
ber of covariates included in the Cox models. Accordingly, we may assign the number of
covariates in the Cox model as a score for each study and treat the score as a study-level
covariate 푧푖 in the meta-regression model (3.10), 푧푖 = 1, 2, . . . , 퐿. However, different covari-
ates, when omitted from the Cox model, will have different effects on the treatment effect
estimation. If two studies have different subsets but the same number of covariates included
in the Cox models, it is problematic to assign the same score to both studies because they are
still incomparable. We wish to define a quantitative variable which could reflect the effects
of different subsets of covariates on the estimation of treatment effect. It is possible that
we could estimate these different effects and put that information into the meta-regression
models to adjust the estimation bias. However, as suggested by Gail et al. (1984) [19], it
requires individual patient data information such as the variance of the omitted covariates
to estimate the bias of treatment effect, which is not available in an APD meta-analysis
setting. Thus, we propose a nonparametric method to rank the covariates and assign scores
to them. Our proposed scoring system is constructed as follows:
1. Assign score 푠푙 to covariate 푋푙, 푙 = 1, 2, . . . , 퐿 so that 푠1 = 1 and
∑퐿
푙=2 푠푙 = (퐿− 1);
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2. If the rank of (푋2, 푋3, . . . , 푋퐿) is (푟2, 푟3, . . . , 푟퐿), where higher rank indicates larger po-
tential bias of estimated treatment effect when that covariate is omitted from the Cox
model, then 푠2 : 푠3 : . . . : 푠퐿 = 푟2 : 푟3 : . . . : 푟퐿.
We can rank (푋2, 푋3, . . . , 푋퐿) based on the absolute values of estimated coefficients
(∣훼ˆ1∣, ∣훼ˆ2∣, . . . , ∣훼ˆ퐿−1∣) from the meta-ANOVA model (3.12). Here, ∣훼ˆ푙−1∣ is the estimated
incremental effect when covariate 푋푙 is included in the Cox model, 푙 = 2, 3, . . . , 퐿. Ad-
ditionally, the ranking should be carefully chosen to be biologically or clinically mean-
ingful in case where two coefficients have very similar values. Furthermore, we use 푧푖 =∑퐿
푙=1 (퐼{푋푙 is included in study 푖} × 푠푙) to denote the score for each study. Hence, 푧푖 is the “study-
level” covariate which has lowest value 1 if only treatment indicator 푋1 is in the Cox model
and has highest value 퐿 if the Cox model includes all 퐿 covariates. Additionally, studies
with the same subsets of covariates share the same value of score 푧푖, and the higher the score
the smaller the bias in treatment effect.
Similar to the conditional linear model proposed by Wu and Bailey (1989) [76], assuming
treatment effect 휃푖 given the score 푧푖 is a polynomial function of 푧푖, we propose a meta-
polynomial model as
(휃푖∣푧푖) = Z′푖휶+ 푎푖 + 휀푖
=
푛∑
푗=0
훼푗(푧푖)
푗 + 푎푖 + 휀푖, (3.15)
where Z푖 = (1, 푧푖, 푧
2
푖 , . . . , 푧
푛
푖 )
′ for each study.
Explicitly, this conditional polynomial model (3.15) can be written as
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
휃1 ∣ 푧1
휃2 ∣ 푧2
휃3 ∣ 푧3
...
휃푘 ∣ 푧푘
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
=
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
1 푧1 푧
2
1 . . . 푧
푛
1
1 푧2 푧
2
2 . . . 푧
푛
2
1 푧3 푧
2
3 . . . 푧
푛
3
...
...
...
...
...
1 푧푘 푧
2
푘 . . . 푧
푛
푘
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
×
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
훼0
훼1
훼2
...
훼푛
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
+
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
푎1
푎2
푎3
...
푎푘
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
+
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
휀1
휀2
휀3
...
휀푘
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
. (3.16)
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If 푧max = max{푧푖} is the score of the Cox model with a full set of covariates, our proposed
pooled treatment effect estimator based on the meta-polynomial model is
휃ˆM-P =
푛∑
푗=0
훼ˆ푗(푧max)
푗
= [ 1 푧max 푧
2
max . . . 푧
푛
max ]× 휶ˆ
= Z′max × 휶ˆ. (3.17)
The variance of 휃ˆM-P is given by
var(휃ˆM-P) = Z
′
maxvar(휶ˆ)Zmax. (3.18)
To better demonstrate our proposed models, suppose that we pooled five studies, gen-
erated from the same data simulation scheme as what we did in Section (3.1.1), to form a
meta-analysis. We arbitrarily removed different covariates from different studies: Study 1
contains only covariate 푋1; Study 2 contains both 푋1 and 푋2; Study 3 contains 푋1, 푋2 and
푋3; Study 4 contains 푋1, 푋4 and 푋5; and Study 5 contains all five covariates. Thus, Study
5 has the “full” Cox model and Study 1-4 have some covariates omitted. Among the five
covariates, 푋1 is the treatment indicator of primary interest and it is always included in all
models. The specifications of the Cox models for the five studies are:
Study 1: ℎ1푗(푡) = ℎ0(푡) exp(훽11푥11푗), 푗 = 1, 2, . . . , 푛1,
Study 2: ℎ2푗(푡) = ℎ0(푡) exp(훽21푥21푗 + 훽22푥22푗), 푗 = 1, 2, . . . , 푛2,
Study 3: ℎ3푗(푡) = ℎ0(푡) exp(훽31푥31푗 + 훽32푥32푗 + 훽33푥33푗), 푗 = 1, 2, . . . , 푛3,
Study 4: ℎ4푗(푡) = ℎ0(푡) exp(훽41푥41푗 + 훽44푥44푗 + 훽45푥45푗), 푗 = 1, 2, . . . , 푛4,
Study 5: ℎ5푗(푡) = ℎ0(푡) exp(훽51푥51푗 + 훽52푥52푗 + 훽53푥53푗 + 훽54푥54푗 + 훽55푥55푗), 푗 = 1, 2, . . . , 푛5,
where 푥푖푙푗 is the value of variable 푋푙 for subject 푗 in study 푖.
In this example, each study 푖 provides a value of 훽ˆ푖1 (denoted as 휃푖) and var(훽ˆ푖1) (denoted
as 휎2푖 ). To combine the 푘 studies to come up with an overall treatment effect estimation, the
meta-ANOVA model can be written as
휃푖 = 훼0 + 훼1 × 푧푖2 + 훼2 × 푧푖3 + 훼3 × 푧푖4 + 훼4 × 푧푖5 + 푎푖 + 휀푖. (3.19)
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Explicitly, equation (3.19) has the form in matrix notation as following
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
휃1
휃2
휃3
휃4
휃5
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
=
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
1 0 0 0 0
1 1 0 0 0
1 1 1 0 0
1 0 0 1 1
1 1 1 1 1
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
×
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
훼0
훼1
훼2
훼3
훼4
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
+
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
푎1
푎2
푎3
푎4
푎5
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
+
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
휀1
휀2
휀3
휀4
휀5
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
, (3.20)
where the intercept term 훼0 is the common treatment effect since treatment variable 푋1 is
always in the models, and 훼푙−1 is the incremental effect when covariate 푋푙 is included in the
Cox model, 푙 = 2, 3, 4, 5.
Since each 푧푖푙 in the four-way meta-ANOVA model (3.19) is a two-level predictor, 푙 =
2, 3, 4, 5, there is a total of 24 = 16 categories of estimated treatment effects 휃푖s. We re-do
Figure 3.1 to plot estimated treatment effects over the 16 categories in Figure 3.3.
From our assumption, only 휃푖s from the “full” models are not biased. Thus our proposed
estimator for the pooled treatment effect bases on the meta-ANOVA model is
휃M-A = 훼ˆ0 + 훼ˆ1 + 훼ˆ2 + 훼ˆ3 + 훼ˆ4
= [ 1 1 1 1 1 ]× 휶ˆ,
= 1′(5) × 휶ˆ. (3.21)
The variance of 휃M-A is given by
var(휃M-A) = 1
′
(5)var(휶ˆ)1(5). (3.22)
We can rank (푋2, 푋3, 푋4, 푋5) based on the absolute values of estimated coefficients
(∣훼ˆ1∣, ∣훼ˆ2∣, ∣훼ˆ3∣, ∣훼ˆ4∣) from the four-way meta-ANOVA model (3.19). In our example, we
rank (푋2(Age), 푋3(Tumor Size), 푋4(ER-Positive), 푋5(Number of Nodes)) as (3, 1, 2, 4),
then the scores for the five covariates are (1, 1.2, 0.4, 0.8, 1.6). Furthermore, we use 푧푖 =∑5
푙=1 (퐼{푋푙 is included in study 푖} × 푠푙) to denote the score for each study. Figure 3.4 illustrates
that there is a strong linear relationship between the estimated treatment effects and scores.
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Figure 3.3: Estimated treatment effects from Cox proportional hazard models with different
categories.
The 푥-axis indicates the categories of the four-way meta-ANOVA model. Category 1 only includes treatment
indicator 푋1 and Category 16 includes all five covariates. Other categories indicate different combinations of
covariates 푋1, . . . , 푋5 but 푋1 is always included. The red dot stands for the median value for each category.
−0.2 is the true coefficient of treatment indicator.
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Figure 3.4: Estimated treatment effects from Cox proportional hazard models with different
scores.
The 푥-axis indicates the score for each study of the proposed meta-polynomial model. Score = 1 indicates
only treatment indicator 푋1 is included. Score = 5 indicates all five covariates are included. The red dot
stands for the median value for each score. −0.2 is the true coefficient of treatment indicator.
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Thus, the conditional polynomial model (3.15) for our example can be written as
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
휃1 ∣ 1.0
휃2 ∣ 2.2
휃3 ∣ 2.6
휃4 ∣ 3.4
휃5 ∣ 5.0
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
=
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
1 1.0 1.02 . . . 1.0푛
1 2.2 2.22 . . . 2.2푛
1 2.6 2.62 . . . 2.6푛
1 3.4 3.42 . . . 3.4푛
1 5.0 5.02 . . . 5.0푛
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
×
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
훼0
훼1
훼2
...
훼푛
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
+
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
푎1
푎2
푎3
푎4
푎5
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
+
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
휀1
휀2
휀3
휀4
휀5
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
. (3.23)
If 푧max = 5.0 is the score of the “full” Cox model, our proposed pooled treatment effect
estimator based on the meta-polynomial model is
휃M-P =
푛∑
푗=0
훼ˆ푗(5.0)
푗
= [ 1 5.0 5.02 . . . 5.0푛 ]× 휶ˆ. (3.24)
The variance of 휃M-P is given by
var(휃M-P) = [ 1 5.0 5.0
2 . . . 5.0푛 ]× var(휶ˆ)× [ 1 5.0 5.02 . . . 5.0푛 ]′. (3.25)
From the previous Section (3.1.1), we demonstrated that the estimated treatment effect
휃푖 is highly dependent on other covariates included in the Cox model. Then for both meta-
ANOVA and meta-polynomial models, Z푖 is the study level characteristic vector which helps
to explain the heterogeneity of treatment effects across studies. Since these two models share
the same general form as equation (3.10), we demonstrate how both parametric maximum
likelihood and nonparametric quadratic method of moments estimations are calculated for
휶 and the heterogeneity variance 휏 2 under the general form of notation.
Maximum Likelihood Estimation
If the assumption of normality of model (3.10) is valid, the log-likelihood is written as
푙(휶, 휏 2) ∝ −1
2
푘∑
푖=1
[
ln(휎2푖 + 휏
2) +
(휃푖 − Z′푖휶)2
휎2푖 + 휏
2
]
. (3.26)
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To use iterative algorithm to get the maximum likelihood estimation (MLE), we need
the first and second derivatives with respect to 휶 and 휏 2:
∂푙
∂휶
=
푘∑
푖=1
(휃푖 − Z′푖휶)Z푖
휎2푖 + 휏
2
,
∂푙
∂휏 2
= −1
2
푘∑
푖=1
[
1
휎2푖 + 휏
2
− (휃푖 − Z
′
푖휶)
2
(휎2푖 + 휏
2)2
]
,
∂2푙
∂휶2
= −
푘∑
푖=1
Z푖Z
′
푖
휎2푖 + 휏
2
= H11,
∂2푙
∂(휏 2)2
=
1
2
푘∑
푖=1
[
1
(휎2푖 + 휏
2)2
− 2(휃푖 − Z
′
푖휶)
2
(휎2푖 + 휏
2)3
]
= 퐻22,
∂2푙
∂휶∂휏 2
= −
푘∑
푖=1
(휃푖 − Z′푖휶)Z푖
(휎2푖 + 휏
2)2
= H12,
∂2푙
∂휏 2∂휶
= −
푘∑
푖=1
Z′푖(휃푖 − Z′푖휶)
(휎2푖 + 휏
2)2
= H21.
And the Hessian matrix for 푙(휶, 휏 2) is
H =
⎡⎣ H11 H12
H21 퐻22
⎤⎦ .
The information matrix is the negative of the expected Hessian matrix
퓘 = −퐸(H) =
⎡⎣ ∑푘푖=1 Z푖Z′푖휎2푖 +휏2 0
0 1
2
∑푘
푖=1
1
(휎2푖 +휏
2)2
⎤⎦ .
The Fisher Scoring (FS) algorithm leads to the MLE of 휶 as
휶ˆ푠+1 = 휶ˆ푠 +
(
푘∑
푖=1
Z푖Z
′
푖
휎2푖 + 휏ˆ
2
푠
)−1 푘∑
푖=1
(휃푖 − Z′푖휶ˆ푠)Z푖
휎2푖 + 휏ˆ
2
푠
=
(
푘∑
푖=1
Z푖Z
′
푖
휎2푖 + 휏ˆ
2
푠
)−1 푘∑
푖=1
(
Z′푖휶ˆ푠Z푖
휎2푖 + 휏ˆ
2
푠
+
(휃푖 − Z′푖휶ˆ푠)Z푖
휎2푖 + 휏ˆ
2
푠
)
=
(
푘∑
푖=1
Z푖Z
′
푖
휎2푖 + 휏ˆ
2
푠
)−1 푘∑
푖=1
Z푖휃푖
휎2푖 + 휏ˆ
2
푠
(3.27)
with a good starting point 휶ˆ0 =
(∑푘
푖=1 휎
−2
푖 Z푖Z
′
푖
)−1 (∑푘
푖=1 휎
−2
푖 Z푖휃푖
)
, where 푠 is the iteration
index.
Then the estimation of heterogeneity variance 휏 2 is the key in our random effect meta-
regression models. It is well known that MLE of variances is biased for finite samples. Thus
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we prefer restricted MLE for our analysis. The restricted log-likelihood of model (3.10) is
written as
푙푅(휶, 휏
2) ∝ −1
2
{
푘∑
푖=1
[
ln(휎2푖 + 휏
2) +
(휃푖 − Z′푖휶)2
휎2푖 + 휏
2
]
+ ln
∣∣∣∣∣
푘∑
푖=1
Z푖Z
′
푖
휎2푖 + 휏
2
∣∣∣∣∣
}
. (3.28)
From matrix calculus we know that ∂(ln(det(M))) = 푡푟(M−1∂M). Then we have the
first derivative with respect to 휏 2 as
∂푙푅
∂휏 2
= −1
2
{
푘∑
푖=1
[
1
휎2푖 + 휏
2
− (휃푖 − Z
′
푖휶)
2
(휎2푖 + 휏
2)2
]
−퐷(휏 2)
}
, (3.29)
where
퐷(휏 2) = 푡푟
⎡⎣( 푘∑
푖=1
Z푖Z
′
푖
휎2푖 + 휏
2
)−1( 푘∑
푖=1
Z푖Z
′
푖
(휎2푖 + 휏
2)2
)⎤⎦ . (3.30)
As Demidenko (2004) [11] pointed out that the information matrices of ML and REML
asymptotically coincide, the FS algorithm for the REML estimation of 휏 2 is
휏ˆ 2푠+1 = 휏ˆ
2
푠 +
(
푘∑
푖=1
1
(휎2푖 + 휏ˆ
2
푠 )
2
)−1 푘∑
푖=1
(
(휃푖 − Z′푖휶ˆ푠)2
(휎2푖 + 휏ˆ
2
푠 )
2
− 1
휎2푖 + 휏ˆ
2
푠
+퐷(휏ˆ푠)
2
)
=
(
푘∑
푖=1
1
(휎2푖 + 휏ˆ
2
푠 )
2
)−1 푘∑
푖=1
(
휏ˆ 2푠
(휎2푖 + 휏ˆ
2
푠 )
2
+
(휃푖 − Z′푖휶ˆ푠)2
(휎2푖 + 휏ˆ
2
푠 )
2
− 1
휎2푖 + 휏ˆ
2
푠
+퐷(휏ˆ푠)
2
)
=
(
푘∑
푖=1
1
(휎2푖 + 휏ˆ
2
푠 )
2
)−1 푘∑
푖=1
(
(휃푖 − Z′푖휶ˆ푠)2 − 휎2푖
(휎2푖 + 휏ˆ
2
푠 )
2
+퐷(휏ˆ푠)
2
)
, (3.31)
where 푠 is the iteration index and a good starting point 휏ˆ 20 = 0.
Quadratic Method of Moments Estimation
The use of likelihood methods assumes model (3.10) following a normal distribution.
However, a quadratic method of moments estimation relaxes this assumption and therefore
is free of distribution. The weighted sum of squares 푄-statistic for heterogeneity test is
푄 =
푘∑
푖=1
휎−2푖 (휃푖 − Z′푖휶ˆ0)2, (3.32)
where 휶ˆ0 is estimated as the starting point in (3.27).
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To calculate the expectation of 푄, we write the general meta-regression model (3.10) in
matrix notation as
휽 = Z휶+ a + 휺, 퐸(a + 휺) = 0, var(a + 휺) = V = 휏 2I + Σ, (3.33)
where Z is a 푘 × (푚+ 1) design matrix, 푘 is the number of studies and 푚 is the number of
covariates included in the meta-regression model, and Σ = 푑푖푎푔(휎21, 휎
2
1, . . . , 휎
2
푘).
From Seber and Lee (2003) [69], if assume vector x with 퐸(x) = c and var(x) = Σ, A is
a symmetric matrix, then
퐸(x′Ax) = 푡푟(AΣ) + c′Ac. (3.34)
Thus, the expectation of 푄 is
퐸(푄) = 퐸
(
푘∑
푖=1
휎−2푖 (휃푖 − Z′푖휶ˆ0)2
)
= 퐸
[
휽′
(
Σ−1 −Σ−1Z(Z′Σ−1Z)−1Z′Σ−1)휽]
= 푡푟
[(
Σ−1 −Σ−1Z(Z′Σ−1Z)−1Z′Σ−1) (휏 2I + Σ)]
+(Z휶)′
(
Σ−1 −Σ−1Z(Z′Σ−1Z)−1Z′Σ−1)Z휶
= 푡푟
[(
Σ−1 −Σ−1Z(Z′Σ−1Z)−1Z′Σ−1) (휏 2I + Σ)]
= 휏 2푡푟
(
Σ−1 −Σ−1Z(Z′Σ−1Z)−1Z′Σ−1)+ 푘 −푚
= 휏 2
(
푘∑
푖=1
휎−2푖 −퐷(0)
)
+ 푘 −푚. (3.35)
If we equate the empirical sum 푄 to its expected value, the weighted method of moments
estimator of 휏 2 has the form
휏ˆ 2푊푀푀 =
푄− (푘 −푚)∑푘
푖=1 휎
−2
푖 −퐷(0)
, (3.36)
where 퐷(0) is defined as in (3.30) when 휏 2 = 0.
However, the estimates may be negative when 푄 < 푘−푚. Accordingly, we truncate the
weighted method of moments estimate as
휏˜ 2푊푀푀 = max(0, 휏ˆ
2
푊푀푀). (3.37)
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The problem with this estimator is that it is slightly positively biased. This bias is often
observed for small between-study heterogeneity.
To test the heterogeneity of treatment effects between studies, under the null hypothesis
퐻0 : 휏
2 = 0 we have
푄 ∼ 휒2(푘 −푚− 1), (3.38)
where 푘 is the number of studies and 푚 is the number of covariates in the meta-regression
model.
3.2 HIERARCHICAL MULTIPLE IMPUTATION
As mentioned in the chapter of literature review, missing covariates is problematic for IPD
meta-analysis using Cox model. However, not only the frequency of missing data but also
the missingness process may vary across studies from which individual data are pooled [40].
Thus current approaches of handling missing covariates for a single study may, therefore, not
be directly implemented for IPD meta-analysis. Furthermore, we mainly focus on another
type of “missing” covariates may occur in the pooled data set: some covariates might not
be observed at all in a specific study included in the IPD meta-analysis. That is to say, a
set of covariates is always missing for some studies in the pooled data set by design. And
within each study, we assume there is no missing data problem. To address this specific
type of missing covariates problem in IPD meta-analysis, we propose a hierarchical multiple
imputation (HMI) method.
As we reviewed at Section (2.1.2), we can pool IPD from 푘 studies and 푛푖 subjects per
study together to form a “mega-trial” so that a single analysis can be perform, 푖 = 1, 2, . . . , 푘.
The total sample size of IPD meta-analysis is thus 푁 =
∑푘
푖=1 푛푖. Also assume we observe
a 푝-dimensional vector of covariates X푖푗 for subject 푗 in study 푖, 푗 = 1, 2, . . . , 푛푖. Then
(푡푖푗, 훿푖푗,X푖푗) are the observed variables, where 푡푖푗 is the observed failure time and 훿푖푗 is the
censoring indicator which equals to 1 if the observed event is a failure and 0 otherwise.
When some of the covariates are subject to missingness, we can write X푖푗 = (X
표푏푠
푖푗 ,X
푚푖푠
푖푗 ) =
((푥표푏푠푖1푗 , 푥
표푏푠
푖2푗 , . . . , 푥
표푏푠
푖푞푗 ), (푥
푚푖푠
푖(푞+1)푗, 푥
푚푖푠
푖(푞+2)푗, . . . , 푥
푚푖푠
푖푝푗 )) which means for the vector X푖푗, the first
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푞 covariates are always completely observed and some of the last (푝 − 푞) covariates are
sometimes omitted from study 푖 by design or by happenstance. Additionally, an indicator
vector O푖푗 = {표푖푙푗}1⩽푙⩽푝 is defined, in which 표푖푙푗 equals to 1 if 푥푖푙푗 is observed and 0 if
푥푖푙푗 is missing. It is highly likely that X푖푗 is a mixture of both categorical and continuous
covariates. So we will use the MIX package developed by Schafer (1997) [68] to impute the
missing data. The procedure of our proposed HMI has several steps:
Step 1. Re-arrange the columns of the covariate matrix X푚푖푠 so that
∑푘
푖=1
∑푛푖
푗=1 표푖(푞+1)푗 ⩾∑푘
푖=1
∑푛푖
푗=1 표푖(푞+2)푗 ⩾ . . . ⩾
∑푘
푖=1
∑푛푖
푗=1 표푖푝푗;
Step 2. Impute 푥푚푖푠푖(푞+1)푗 with X
표푏푠
푖푗 to get 푥˜
푚푖푠
푖(푞+1)푗;
Step 3. Impute 푥푚푖푠푖(푞+2)푗 with (X
표푏푠
푖푗 , 푥˜
푚푖푠
푖(푞+1)푗) to get 푥˜
푚푖푠
푖(푞+2)푗. Carry the imputation forward
until 푥푚푖푠푖푝푗 is imputed, then the data set is complete;
Step 4. Analyze this complete data set with frailty model to get the treatment effect esti-
mate 휃ˆ1 and its variance 휎ˆ
2
1 for the first imputation;
Step 5. Repeat Step 1-4 푀 times.
Then, our proposed HMI estimate for the pooled treatment effect 휃 is given by
휃ˆHMI =
1
푀
푀∑
푚=1
휃ˆ푚. (3.39)
The variance of 휃ˆHMI has two components of variability: one is the average within-
imputation variance
휎¯2 =
1
푀
푀∑
푚=1
휎ˆ2푚; (3.40)
and the other is the between-imputation variance
휏 2 =
1
푀 − 1
푀∑
푚=1
(휃ˆ푚 − 휃ˆHMI)2. (3.41)
Thus the total variance is the sum
var(휃HMI) = 휎¯
2 +
(
1 +
1
푀
)
휏 2, (3.42)
where 1/푀 is the adjustment for finite 푀 .
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The overall standard error is the square root of var(휃HMI). Confidence intervals are
obtained by taking the overall estimate 휃HMI plus or minus the standard error multiplied by
some number, where that number is a quantile of Student’s 푡−distribution with degree of
freedom
휈 = (푀 − 1)
(
1 +
휎¯2
(1 + 1/푀)휏 2
)2
. (3.43)
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4.0 SIMULATION AND DATA EXAMPLE
In this chapter, we will use data simulation to investigate the performance of different
methodologies we proposed and compare them to the the standard approaches people use
in their meta-analyses. These simulations are implemented to mimic real clinical data in
breast cancer research. The simulations were programed with the R language and executed
on a PC with Intel R⃝CoreTM2 Duo CPU and 3.0 GB memory(RAM). Later in this chapter,
the proposed meta-analysis methodologies are implemented to a data example.
4.1 SIMULATION
4.1.1 Comparison of Methodologies for APD Meta-Analysis
To begin our simulation study, we assumed that we had a total of 푘 studies included in
the APD meta-analysis, and thus generated the survival data for each study 푖 using a Cox
proportional hazard model given by
ℎ푖푗(푡) = ℎ0(푡) exp(훽푖1푥푖1푗 + 훽푖2푥푖2푗 + 훽푖3푥푖3푗 + 훽푖4푥푖4푗 + 훽푖5푥푖5푗). (4.1)
This is a similar data generating scheme as what we did in Section (3.1.1), where the baseline
failure time is generated from an exponential distribution with parameter 휆0 = 0.1 and
푖 = 1, 2, . . . , 푘, 푗 = 1, 2, . . . , 푛푖.
The covariates, 푋1 and 푋4, are categorical variables and 푋2, 푋3 and 푋5 are continuous
variables. To simulate data similar to that observed in a breast cancer clinical trial, we
generated 푋1 from a Bernoulli distribution with 푝 = 0.5 to represent a treatment indicator,
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푋2 as a covariate of centered age from a normal distribution with mean 0 and variance
100 and 푋3 as a covariate of tumor size generated from a 휒
2 distribution with 3 degrees
of freedom. 푋4 is a Bernoulli variable with 푝 = 0.6, representing an indicator of estrogen
receptor positivity and 푋5 stands for number of lymph nodes involved with the breast cancer,
which was generated using an exponential distribution with rate 1/3 and rounded up to
integers but was modified so that negative nodal status (푋5 = 0) would occur in roughly
60% of the patients. To generate the survival times, the coefficients associated with 푋1-푋5
were set to
휷 = (훽1, 훽2, 훽3, 훽4, 훽5)
′ = (−0.2,−0.1, 0.1,−0.15, 0.7)′.
However, the number of patients, 푛푖, for each study was randomly picked from a uniform
distribution with endpoints 100 and 500, and the survival times for each study were censored
with probabilities uniformly randomly chosen between 0.1 and 0.3, inclusively. After gener-
ating the data, each study was randomly fitted with either a correctly specified Cox model
with all five covariates or a misspecified Cox model with some covariates but 푋1 omitted.
Next, we obtained the treatment effect 휃푖(= 훽ˆ1) and its variance 휎
2
푖 (= var(훽ˆ1)) from each
study. Additionally, if we denote the model information, such as which covariates are in-
cluded in the Cox model, as ℱ푖, then (휃푖, 휎2푖 ,ℱ푖) represents the observed APD information
for study 푖, 푖 = 1, 2, . . . , 푘.
Our proposed meta-ANOVA (M-A) model and meta-polynomial (M-P) model are imple-
mented to analyze the observed APD, which are compared with commonly used DerSimonian
and Laird (DL) random effect model. There are two objectives for this simulation study:
1. Compare the the accuracy of the three methodologies using estimation biases;
2. Compare the efficiency of the three methodologies using estimated standard errors.
The data generating and simulation program for APD meta-analysis is listed in Appendix
A.
The results of comparison are shown in the following two figures for 200 simulation:
In Figure 4.1, the number of studies included in the APD meta-analysis varies from 10 to
30. There is little fluctuation of the estimation bias for all three models. Among them, DL
constantly yielded biases > 0.05 while our two proposed methods had small biases around 0.
49
When the number of studies is small, M-A had larger biases than M-P, which results from
the M-A model requiring more covariates, thus, it has a great danger of over-fitting when 푘
is small. As 푘 increases, the biases of M-A decrease and gradually overlap that in the plot
of M-P biases.
In Figure 4.2, the standard error of DL model is much smaller than our proposed methods
due to the fact that it includes no covariates. The standard error of M-P estimator is
consistently smaller than the M-A estimator, especially when the number of studies 푘 is
small.
Another issue is how our proposed models perform compared with DL, if we fix 푘 but
vary 훽1 when generating the data sets. Thus, in the second simulation study, we fixed
푘 = 20 and varied 훽1 from −1.0 to −0.1 while other coefficients were left unchanged. In
Figure 4.3, the bias of the DL estimator becomes considerably large when 훽1 reaches −1.0
and goes down linearly as 훽1 increases. However, our proposed methods have consistently
small biases around 0 and the M-P estimator yields smaller biases than the M-A estimator.
Figure 4.4 illustrates the standard error for each method in the second simulation study. We
can see that the DL estimator has relatively smaller errors than the other two. The M-A
and M-P estimators have similar efficiency but the standard error for M-P is a little smaller.
4.1.2 Comparison of Methodologies for IPD Meta-Analysis
Following the same data generating scheme as what we did in Section (4.1.1), we generated
survival data for 푘 studies and pooled them together study by study. Similarly, the sample
size of each study was uniformly randomly picked from 100 to 500, and the survival times for
each study were censored with probabilities randomly chosen between 0.1 and 0.3, inclusively.
In a randomized clinical trial, treatment indicator (푋1) is always recorded, and we believe age
(푋2) is always (and easy to be) observed, too. So to create the pooled IPD with missingness,
we arbitrarily and randomly pick one of the 푘 studies with no observations of ER status (푋4),
two studies with no observations of tumor size (푋3) and three studies with no observations
of nodal status (푋5). With the help of MIX package developed by Schafer (1997) [68], we
used the information from fully observed covariates (푋1, 푋2) to impute 푋4 and denoted the
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Figure 4.1: Comparison of estimation bias with different numbers of studies
The 푥-axis indicates the number of studies included in the APD meta-analysis. DL: DerSimonian and Laird
random effect model; M-A: meta-ANOVA model; M-P: meta-polynomial model. Each point on the graphs
is averaged over 200 simulation realizations.
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Figure 4.2: Comparison of standard error estimate with different numbers of studies
The 푥-axis indicates the number of studies included in the APD meta-analysis. DL: DerSimonian and Laird
random effect model; M-A: meta-ANOVA model; M-P: meta-polynomial model. Each point on the graphs
is averaged over 200 simulation realizations.
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Figure 4.3: Comparison of estimation bias with different values of coefficient
The 푥-axis is the true value of 훽1 from a Cox proportional hazard model ranging in values from −1.0 to
−0.1. DL: DerSimonian and Laird random effect model; M-A: meta-ANOVA model; M-P: meta-polynomial
model. Each point on the graphs is averaged over 200 simulation realizations.
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Figure 4.4: Comparison of standard error estimate with different values of coefficient
The 푥-axis is the value of 훽1 from −1.0 to −0.1. DL: DerSimonian and Laird random effect model; M-
A: meta-ANOVA model; M-P: meta-polynomial model. Each point on the graphs is averaged over 200
simulation realizations.
54
imputed covariate as 푋˜4. Then 푋3 was imputed based on (푋1, 푋2, 푋˜4). Lastly, 푋5 was
imputed based on (푋1, 푋2, 푋˜3, 푋˜4). Later, a gamma frailty model was used to analyze the
imputed dataset and coefficients and their variances were recorded for comparison under
different data generating scenarios. The above procedure was repeated 푀 times for the
hierarchical multiple imputation. The data generating and simulation program for IPD
meta-analysis is listed in Appendix B.
The true coefficients of (푋1, 푋2, 푋3, 푋4, 푋5) used to generate the survival data were
set as (−0.2,−0.1, 0.1,−0.15, 0.7) as before. In Table 4.1, we compared the mean estimated
coefficients and their standard errors with 10 imputations (푀 = 10). “Full” represents
the situation that there is no missing covariates in the pooled data set. “MIX (Total)”
means that we use the MIX package to impute the missing covariates (푋3, 푋4, 푋5) all
at once, which is the most conventional method to implement data imputation. “MIX
(HMI)” means that we use the MIX package to impute the missingness using the hierarchical
method as described above. When only 10 studies were pooled (푘 = 10), all the estimated
coefficients are underestimated (absolute-value-wise) with noticeable bias, especially for 푋5
which has the most frequent missingness (roughly 30%). When more studies were pooled
together (푘 = 20), all the estimated coefficients moved toward the true values but still were
underestimated (absolute-value-wise). When we pooled 30 studies, the estimated coefficients
had very good estimation accuracy except for 훽ˆ5, which mainly because of the substantial
missingness in 푋5. Through out all the scenarios, the proposed HMI method consistently
had better estimation accuracy than the convetional method. Both imputation methods did
not increase the standard errors and thus had similar effciency as when the full data were
analyzed.
As can be seen from Figure 4.5, when we increased the number of imputation gradu-
ally from 10 to 50, the estimation accuracy of the treatment effect did not improve as 푀
increased, and the confidence intervals remained the same width. Thus, we believe for mul-
tiple imputation with the MIX package, 푀 = 10 is adequate enough to reach the estimation
accuracy and reflect the sampling variability.
Later, we want to investigate the influence of missingness frequency on the estimation
accuracy of all the coefficients. Suppose there are 20 studies pooled together. If we define
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Table 4.1: Mean estimated coefficients (and standard errors) with different number of studies
from 10 imputations
푘 = 10 푘 = 20 푘 = 30
푋1 True 훽1 −0.20 −0.20 −0.20
Full −0.21 (0.058) −0.22 (0.040) −0.20 (0.033)
MIX (Total) −0.14 (0.058) −0.16 (0.040) −0.18 (0.035)
MIX (HMI) −0.15 (0.058) −0.18 (0.041) −0.19 (0.034)
푋2 True 훽2 −0.10 −0.10 −0.10
Full −0.10 (0.001) −0.10 (0.001) −0.10 (0.001)
MIX (Total) −0.07 (0.001) −0.08 (0.001) −0.08 (0.001)
MIX (HMI) −0.08 (0.001) −0.08 (0.001) −0.09 (0.001)
푋3 True 훽3 0.10 0.10 0.10
Full 0.10 (0.010) 0.10 (0.010) 0.10 (0.001)
MIX (Total) 0.06 (0.014) 0.07 (0.010) 0.08 (0.001)
MIX (HMI) 0.06 (0.014) 0.08 (0.010) 0.08 (0.001)
푋4 True 훽4 −0.15 −0.15 −0.15
Full −0.16 (0.059) −0.15 (0.041) −0.15 (0.035)
MIX (Total) −0.10 (0.060) −0.11 (0.042) −0.10 (0.035)
MIX (HMI) −0.12 (0.060) −0.12 (0.041) −0.12 (0.034)
푋5 True 훽5 0.70 0.70 0.70
Full 0.69 (0.020) 0.71 (0.014) 0.70 (0.010)
MIX (Total) 0.25 (0.014) 0.43 (0.010) 0.52 (0.010)
MIX (HMI) 0.29 (0.014) 0.49 (0.010) 0.54 (0.010)
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the missing covariates scenario described above as “Severe”, in which one study has 푋4
missing, two studies have 푋3 missing and three studies have 푋5 missing, then we can define
a “Moderate” missing covariates scenario as one study has 푋3 missing and two studies have
푋5 missing. Subsequently, we can define a “Mild” missing covariates scenario as only one
study has 푋5 missing. In Table 4.2, we compared the mean estimated coefficients and their
standard errors with 10 imputations. In the “Mild” scenario, HMI method reduces to the
conventional method since there is only one covariate subject to missingness, so MIX (Total)
and MIX (HMI) have the same values of estimated coefficients and the accuracy is very
good. In the “Moderate” scenario, the estimated coefficients are slightly biased toward zero
and in the “Severe” scenario, the bias is even more obvious. Based on these results, we can
conclude that both the conventional method and our proposed HMI method are sensitive
to the frequency of missingness. In our simulation studies, if more covariates are subject
to more frequent missingness, the estimated coefficients would have larger bias toward zero.
However, the frequency of missingness does not influence the efficiency of estimation quite
well.
In conclusion, our proposed HMI method has somewhat better estimation accuracy than
the conventional imputation method, using the MIX package from R. However, this accuracy
is highly dependent on the frequency of missingness. When there is substantial proportion of
patients with covariates subject to missingness, the estimated coefficients from the gamma
frailty model are tend to be biased toward zero. The estimation from multiple imputation
using MIX package is as efficient as using the full data set without any missing covariates.
4.2 DATA EXAMPLE
4.2.1 Comparison of Methodologies for APD Meta-Analysis
To assess the average effect on overall survival of positive-node breast cancer patients receiv-
ing “more” chemotherapy (hypothesized by some investigators to improve outcome) versus
those receiving “less” chemotherapy (control group: including no chemotherapy), we com-
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Figure 4.5: Comparison of estimated treatment effect with 95% CI for different numbers of
imputations
The 푥-axis is the numbers of imputations from 10 to 50. Dashed line represents the true value −0.2 of 훽1.
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Table 4.2: Mean estimated coefficients (and standard errors) with 10 imputations in different
missing covariates scenarios
Mild Moderate Severe
푋1 True 훽1 −0.20 −0.20 −0.20
Full −0.20 (0.041) −0.19 (0.041) −0.22 (0.040)
MIX (Total) −0.19 (0.042) −0.16 (0.041) −0.16 (0.040)
MIX (HMI) −0.19 (0.042) −0.18 (0.041) −0.18 (0.041)
푋2 True 훽2 −0.10 −0.10 −0.10
Full −0.10 (0.001) −0.10 (0.001) −0.10 (0.001)
MIX (Total) −0.09 (0.001) −0.08 (0.001) −0.08 (0.001)
MIX (HMI) −0.09 (0.001) −0.08 (0.001) −0.08 (0.001)
푋3 True 훽3 0.10 0.10 0.10
Full 0.10 (0.010) 0.10 (0.010) 0.10 (0.010)
MIX (Total) 0.09 (0.010) 0.08 (0.010) 0.07 (0.010)
MIX (HMI) 0.09 (0.010) 0.09 (0.010) 0.08 (0.010)
푋4 True 훽4 −0.15 −0.15 −0.15
Full −0.15 (0.042) −0.15 (0.042) −0.15 (0.041)
MIX (Total) −0.14 (0.042) −0.11 (0.042) −0.11 (0.042)
MIX (HMI) −0.14 (0.042) −0.13 (0.042) −0.12 (0.041)
푋5 True 훽5 0.70 0.70 0.70
Full 0.70 (0.014) 0.71 (0.014) 0.71 (0.014)
MIX (Total) 0.63 (0.014) 0.51 (0.010) 0.43 (0.010)
MIX (HMI) 0.63 (0.014) 0.53 (0.010) 0.49 (0.010)
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bined four NSABP clinical trials B-15, B-16, B-22 and B-25 to carry out a meta-analysis.
The individual-level covariates considered are treatment (푋1 = 0 if less chemotherapy; = 1
if more chemotherapy), age (푋2: age at entry) and number of positive nodes (푋3 = 1 if 1-4
nodes; = 2 if 4+ nodes). If the Cox proportional hazard models for these four clinical trials
include all three covariates, the estimated log hazard ratios 훽ˆ푖1 are listed in the second col-
umn of the first part of Table 4.3. The 푄 test for heterogeneity is not significant (푝 = 0.61).
Thus the DL estimator degenerates to the inverse variance (IV) fixed effect estimator and
hence the pooled treatment effect is −0.057. When only 푋3 is omitted from all four Cox
models, the pooled treatment effect decreases to −0.048 and when only 푋2 is omitted, the
pooled treatment effect decreases to −0.053. If all four models include only 푋1, the pooled
estimate becomes −0.045. This supports our findings that the treatment effect in Cox model
will be biased toward zero if important covariates are omitted from the model, and the more
covariates omitted, the larger the bias. Additionally, since 푋3 (number of positive nodes) is
a stronger predictor than 푋2 (age), the bias is larger when 푋3 is omitted than when 푋2 is
omitted.
To further demonstrate our proposed methods, we arbitrarily removed different covariates
from only two of the studies, B-15 and B-25. The specifications of the Cox models are list
below:
Study 1: B-15 ℎ1(푡) = ℎ0(푡) exp(훽11푥11),
Study 2: B-16 ℎ2(푡) = ℎ0(푡) exp(훽21푥21 + 훽22푥22 + 훽23푥23),
Study 3: B-22 ℎ3(푡) = ℎ0(푡) exp(훽31푥31 + 훽32푥32 + 훽33푥33),
Study 4: B-25 ℎ4(푡) = ℎ0(푡) exp(훽41푥41 + 훽43푥43).
Thus, only the Cox models for B-16 and B-22 are “correctly specified”. Suppose also that we
have only the estimated treatment coefficients 훽ˆ푖1 (denoted as 휃푖) and its variance var(훽ˆ푖1)
(denoted as 휎2푖 ) available from each of the studies, which we index with 푖 = 1, 2, 3, 4. Then
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Table 4.3: Estimated log hazard ratios from Cox proportional hazard models with different
model specifications and corresponding meta-analysis results
Protocol 훽ˆ푖1 var(훽ˆ푖1) Covariates in 푄 Test
a 훽ˆ1,IV
b var(훽ˆ1,IV)
Cox Models
B-15 −0.061 0.0038
푋1, 푋2, 푋3 푝 = 0.61 −0.057 0.0012
B-16 −0.142 0.0061
B-22 −0.007 0.0044
B-25 −0.039 0.0047
B-15 −0.051 0.0038
푋1, 푋2 푝 = 0.58 −0.048 0.0012
B-16 −0.140 0.0061
B-22 −0.004 0.0044
B-25 −0.020 0.0047
B-15 −0.060 0.0038
푋1, 푋3 푝 = 0.70 −0.053 0.0012
B-16 −0.126 0.0061
B-22 −0.006 0.0044
B-25 −0.039 0.0047
B-15 −0.049 0.0038
푋1 푝 = 0.65 −0.045 0.0012
B-16 −0.126 0.0061
B-22 −0.005 0.0044
B-25 −0.020 0.0047
a 휒2 test with 3 degrees of freedom.
b IV: inverse variance fixed effect estimator.
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the meta-ANOVA model in matrix form can be written as⎡⎢⎢⎢⎢⎢⎢⎣
휃1
휃2
휃3
휃4
⎤⎥⎥⎥⎥⎥⎥⎦ =
⎡⎢⎢⎢⎢⎢⎢⎣
1 0 0
1 1 1
1 1 1
1 0 1
⎤⎥⎥⎥⎥⎥⎥⎦×
⎡⎢⎢⎢⎣
훼0
훼1
훼2
⎤⎥⎥⎥⎦+
⎡⎢⎢⎢⎢⎢⎢⎣
푎1
푎2
푎3
푎4
⎤⎥⎥⎥⎥⎥⎥⎦+
⎡⎢⎢⎢⎢⎢⎢⎣
휀1
휀2
휀3
휀4
⎤⎥⎥⎥⎥⎥⎥⎦ . (4.2)
Our proposed estimator for the pooled treatment effect based on the meta-ANOVA model
is
휃M-A = 훼ˆ0 + 훼ˆ1 + 훼ˆ2
= −0.063 (4.3)
with variance 0.0025.
In this example, we rank [푋2, 푋3] as (1, 2) since we believe number of positive nodes is a
stronger predictor than age at entry. Consequently, following the scoring system described
earlier, the scores associated with [푋1, 푋2, 푋3] are (1, 0.67, 1.33). Explicitly, the conditional
polynomial model (3.15) can then be written as
⎡⎢⎢⎢⎢⎢⎢⎣
휃1 ∣ 1.00
휃2 ∣ 3.00
휃3 ∣ 3.00
휃4 ∣ 2.33
⎤⎥⎥⎥⎥⎥⎥⎦ =
⎡⎢⎢⎢⎢⎢⎢⎣
1 1.00 1.002 . . . 1.00푛
1 3.00 3.002 . . . 3.00푛
1 3.00 3.002 . . . 3.00푛
1 2.33 2.332 . . . 2.33푛
⎤⎥⎥⎥⎥⎥⎥⎦×
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
훼0
훼1
훼2
...
훼푛
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦
+
⎡⎢⎢⎢⎢⎢⎢⎣
푎1
푎2
푎3
푎4
⎤⎥⎥⎥⎥⎥⎥⎦+
⎡⎢⎢⎢⎢⎢⎢⎣
휀1
휀2
휀3
휀4
⎤⎥⎥⎥⎥⎥⎥⎦ . (4.4)
If we only use the first polynomial term and the score of the “full” Cox model is 3, our
proposed pooled treatment effect estimator based on the meta-polynomial model is
휃M-P = [ 1 3 ]× 휶ˆ
= −0.058 (4.5)
with variance 0.0021.
If we apply the IV method for this example, the pooled treatment effect is −0.053 (with
variance 0.0011) and is biased toward zero as compared to the true value of −0.057 from
Table 4.3. However, the M-P estimator has good accuracy but with a relatively larger
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variance compared to the IV estimator. The M-A estimator is somewhat biased low largely
because of the small number of studies included in the meta-regression.
There are 256 different ways to choose one set of B-15, B-16, B-22 and B-25 from the
first column of Table 4.3. Each box plot in Figure 4.6 shows the pooled treatment effects
from all the 256 meta-analyses for one of the three estimators. The results concur with our
simulation analyses that the simple meta-analysis method (IV) has pooled treatment effects
biased toward zero. Our proposed APD meta-regression models have better estimation
accuracy but larger variance.
4.2.2 Comparison of Methodologies for IPD Meta-Analysis
To better demonstrate our proposed methods for IPD meta-analysis, we again pooled four
NSABP clinical trials B-15, B-16, B-22 and B-25 with individual patient data and this time,
we included another covariate to represent ER status (푋4 = 1 if ER-positive; = 0 if ER-
negative), besides the already included covariates treatment (푋1), age (푋2), and number of
positive nodes (푋3). Further, we assume that one out the four trials has 푋4 missing and
two out the four have 푋3 missing. Then, we implement the MIX package to do the multiple
imputation 10 times with both the conventional way and our proposed HMI method. A
gamma frailty model was later used to analyzed the imputed data set. The results are
compared with the full data set and listed in Table 4.4. We could see that the estimated
coefficients with imputed data set all have very good estimation accuracy, except for 푋3 since
it has almost 50% of its observations missing. Again, across all covariates, the proposed HMI
method has better estimation accuracy than the conventional method, and both methods
have similar efficiency when compared with the results from a full data set.
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Figure 4.6: Comparison of estimation of the pooled treatment effect from three estimators
IV: inverse variance fixed effect model; M-A: meta-ANOVA model; M-P: meta-polynomial model.
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Table 4.4: Mean estimated coefficients (and standard errors) with 10 imputations for NSABP
data
푋1 푋2 푋3 푋4
Full −0.050 (0.035) 0.003 (0.001) 0.790 (0.033) −0.242 (0.035)
MIX (Total) −0.044 (0.035) 0.004 (0.001) 0.396 (0.033) −0.221 (0.035)
MIX (HMI) −0.047 (0.035) 0.004 (0.001) 0.458 (0.033) −0.236 (0.035)
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5.0 DISCUSSION AND CONCLUSIONS
5.1 APD META-ANALYSIS
Modeling heterogeneity across studies is a key issue in meta-analysis, especially in APD set-
tings where we have limited information regarding treatment effect from each trial. Since, in
APD settings, we only observe effect sizes and summarized model information from different
studies, it is challenging to combine estimates of the treatment effects from Cox proportional
hazard models where adjustments have been made for different subsets of covariates. It has
been established that estimation biases are likely to be high in cases where non-randomized
studies are combined. However, estimates of treatment effects may also be biased in Cox pro-
portional hazard models in randomized prospective trials if one fails to adjust for prognostic
variables even when the covariates are perfectly balanced across treatment groups using ran-
domization [4]. At first glance, this statement seems counterintuitive because no such bias
would occur from omitting perfectly balanced prognostic variables in the more familiar lin-
ear regression model, even though some efficiency would be lost in estimating the treatment
effect [19]. Hauck et al. (1998) [25] provided an intuitive explanation regarding this unique
problem in non-linear regression models such as Cox proportional hazard model: models
with a “full” set of covariates measure the best reflection of the risks or benefits for patients
with specific covariate values, which they called “subject-specific” models. In contrast, the
treatment effects from models with some covariates omitted is a comparison of averaged out-
comes, where the averaging is over all omitted covariates. In the extreme case where a Cox
model has only treatment variable, the treatment effect is a population average comparing all
different outcomes in groups of patients. Thus, the latter are called “population-averaged”
models. Further, adding more covariates moves the population-averaged models closer to the
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subject-specific models and subsequently, changes the interpretation of treatment effects.
Obviously, there are other sources of heterogeneity associated with treatment effects.
Different clinical trials may use different treatment protocols and have different study de-
signs. Additionally, the sets of baseline covariates collected such as demographic variables
or clinical or pathologic variables may vary substantially across studies, and such variables
are likely to be related to outcomes. In addition, there is selection bias, publication bias,
data irregularities and other debatable fundamental issues with meta-analysis [15]. These
problems can generally be avoided if a few basic principles are observed, such as a prior defi-
nition of inclusion criteria for studies and a comprehensive trial search strategy [14]. Similar
to the need to carefully design clinical trials, meta-analyses also need to be carefully planned
with detailed written protocols being prepared in advance. We do not address topics of the
selection process or publication bias associated with meta-analyses in this dissertation, but
rather assume all studies share certain common characteristics and that a “full” Cox model
is globally best for all studies. Here, the “full” Cox model is chosen from one or more studies
where the largest number of covariates are measured and included, and other studies are
designated as having some covariates omitted.
Similar to the regular linear regression models, our proposed meta-regression models work
better with larger sample sizes, which, in the particular case of APD meta-analysis, means
more clinical trials should be included. This is especially true for a meta-ANOVA model
which usually requires more covariates and one is in danger of over fitting when the number
of studies is small. As of now, there is no globally accepted guideline of how many studies
should be pooled to design a meta-analysis. With the booming development of the internet
and information searching technology, identifying and locating relevant studies may be easily
achieved. For published studies, electronic databases are useful. The Cochrane Central
Register of Controlled Trials [29] has provided extensive searches of medical journals in
English and many other languages and is probably the best single electronic source of clinical
trials for meta-analyses. Thus, including as many studies as possible which meet the pre-
specified selection criteria in a meta-analysis will provide better results when implementing
the meta-regression models.
Another issue with the meta-polynomial model is how to score covariates. The analytic
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procedure proposed in this paper scores the covariates included in the Cox model based on
their ranks. However, the method to rank covariates is somewhat arbitrary and thus, different
researchers many have different options to assign scores. One needs to gather as much
information as possible from literature reviews and expert advice to explore different ways
of ranking the covariates. In some cases, sensitivity analyses should be performed to explore
the robustness of scoring procedures. Additionally, a plot of the observed treatment effects
over the scores of studies could be very helpful. The usual stepwise regression technique can
be used to determine the lowest-degree polynomial that fits the APD best.
The random effect method provided by DerSimonian and Laird (1986) [13] allows for
treatment effects to vary across studies and uses a simple non-iterative method to esti-
mate the between-study treatment effect variance. Because it incorporates differences into
the analysis of overall treatment efficacy, and because of its simplicity, this estimator has
been widely used. However, this method does not address problems of combining incom-
parable Cox models caused by omitting covariates. Our proposed meta-ANOVA and meta-
polynomial models outperform the existing method in the presence of the “incomparability”
issue. Both estimators produce very accurate estimation with price of losing a small amount
of efficiency. Further, the meta-polynomial method performs better than the meta-ANOVA
with a smaller bias and a smaller standard error, especially when the number of studies
included in the APD meta-analysis is small.
5.2 IPD META-ANALYSIS
Although due to the time or financial constrains, IPD meta-analysis is not as prevalent as
APD meta-analysis, it is however viewed as the gold standard of doing meta-analysis, and
researchers should try their best to obtain individual data, which has enormous advantages
where we stated at the beginning of Section (2.1.2) in details. However, problems of missing
covariates complicate IPD meta-analysis, and especially for IPD meta-analysis using Cox
regression model which requires full covariate information. We proposed the solution for the
missing covariates problems via a hierarchical multiple imputation (HMI) method.
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From the simulation study (in Section (4.1.2)) and real data analysis (in Section (4.2.2)),
the HMI method is consistently superior than the conventional imputation method which
imputes all missing covariates at the same time. The reason behind this phenomenon is
that, for the conventional way, it only utilizes the information from all the covariates without
missing value across all studies, which could be only a small portion of the whole information
the full data set holds if the frequency of missingness is severe. In a hypothetic example
of an IPD meta-analysis combining six studies, as depicted in Figure 5.1, we only use the
information from study 4, 5 and 6 to do the imputation in the conventional way. However,
for the HMI method, we utilize the information of fully observed information from the
covariates without missing value to impute the first covariate with the smallest percentage
of missingness, which means we use all the information from 푋1 and 푋2 across all six studies
to impute 푋3. Then we combined the imputed 푋3 with 푋1 and 푋2 to impute 푋4. In this
way, we utilize the maximum amount of information we could get out from this data set.
Thus, HMI could improve the accuracy of the estimation based on the imputed data set.
We also observed that the estimated coefficients for the covariates with considerably large
amount of missingness could be highly biased, no matter which imputation methods were
used or how many times of imputations were implemented. Missing data problem should be
thoroughly investigated when conducting a IPD meta-analysis. We should not assume the
imputed data set as the true “full” data set and take whatever conclusion we could get for
granted. Besides, in this dissertation, we only consider the situation where some covariates
are omitted as a whole chunk from certain studies so that there is not a single observation.
Other than that, we assume there is no missing data problem within each observed covariate.
If the second type of missing data problem exists, further analysis should be implemented
to tackle this problem.
However, the fundamental assumption we made for the validity of the hierarchical mul-
tiple imputation, or other likelihood or weighted estimating equation methods, is that the
distributions of covariates are the same across all studies, which means all the studies in-
cluded in an IPD meta-analysis should share the same study design, same protocol, and same
patient baseline characteristics. This could be somehow achieved by planning a carefully de-
signed selection criteria and a comprehensive study searching strategy. But, still, this is a
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Study 1
X1         X2         X3         X4         X5
 
Study 2
Study 3
MIX (HMI)
Study 4
 
Study 5 MIX (Total)
Study 6
Figure 5.1: Comparison of MIX (HMI) and MIX (Total) in a hypothetic IPD meta-analysis
MIX (HMI): the proposed hierarchical multiple imputation; MIX (Total): the conventional way to impute
all missingness together at once.
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very aggressive assumption and often it is open to questions when doing a meta-analysis in
a real world. The proposed HMI method utilizes the maximum amount of information from
the data set as a whole and could best reflect the variability and heterogeneity of covariates
across studies, that is the reason why it is more appropriate than the conventional imputa-
tion method in the IPD meta-analysis. However, caution has to be taken when interpreting
the results from HMI method and the descriptive statistics of the baseline characteristics
could help us to make the right decision.
Thus, for IPD meta-analysis, our recommendation is to take the two-stage approach as
we discussed in Section (2.1.2.2). The purpose of doing a meta-analysis is twofold: one is
to get the combined treatment effect estimation; the other is to assess the heterogeneity
of treatment effects across studies and explore why. The IPD meta-analysis will simply
not provide the latter information. By doing a two-stage IPD meta-analysis, we can get
estimated treatment effect from each study via a standard Cox proportional hazard model
and then combine them with the general APD meta-analysis methods. Or if the missing
covariates problem persists, the proposed meta-ANOVA model or meta-polynomial model
could be used. However, future works which might have better results are list in the next
section.
5.3 FUTURE WORKS
In this section, we present two directions for future work. One is an attempt to extend the
existing weighted estimating equation for IPD meta-analysis with missing covariates problem.
The other one is a proposal of integrating the information provided by IPD meta-analysis
into APD meta-analysis based on the findings of Gail et al. (1984) [19].
5.3.1 Multiple Missingness Weighted Estimating Equation (MMWEE)
As we asserted in Section (2.2.3), the weighted estimating equation (WEE) method works
best when there is only one covariate subject to missingness, or when all elements of X푚푖푠푖푗 are
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always observed or unobserved. However, either scenario is unlikely to occur in a IPD meta-
analysis. Thus, we may extend the usual WEE to accommodate multi-missingness patterns
of X푚푖푠푖푗 and we call it a “multiple missingness weighted estimating equation” (MMWEE).
Without loss of generality, we will demonstrate multi-missingness with a simple example.
More complicated cases are easy to envision. Suppose we have five covariates 푋1 −푋5 but
only 푋4 and 푋5 are subject to missingness. If we have 표푖푙푗 defined as before, a hypothetic
IPD of 표푖푙푗 are shown in Table (5.1(a)). Previous WEE methods can only handle missing
patterns such as in Study 1 and Study 4, but not in Study 2 and Study 3. Assuming that
there is no within-study missing data problem, it implies that 표푖푙푗 have the same value for all
푗 within one study. Thus, we can remove the subscript 푗 and have 표푖푙 to denote the indicator
of observed covariate 푙 in study 푖, as in Table (5.1(b)).
Because only two covariates might be missing for some studies, there are 22 = 4 types of
missing patterns. Therefore, we create four new indicator variables for each study 푖 as
R푖 = (푅푖1, 푅푖2, 푅푖3, 푅푖4)
⎧⎨⎩
푅푖1 = 퐼{표푖4=1 and 표푖5=1}
푅푖2 = 퐼{표푖4=1 and 표푖5=0}
푅푖3 = 퐼{표푖4=0 and 표푖5=1}
푅푖4 = 퐼{표푖4=0 and 표푖5=0}
.
R is thus a Multi-Bernoulli variable with probabilities (휋1, 휋2, 휋3, 휋4),
∑4
푎=1 휋푎 = 1. It is safe
to assume MACR in our IPD meta-analysis, since R does not depend on either 푦푖, X
표푏푠
푖 or
X푚푖푠푖 . Now we can extend the score function (2.44) to be
uMMWEE(휷) =
푘∑
푖=1
{
푅푖1
휋1
u푖(휷∣푦푖,X표푏푠푖 ,X푚푖푠푖 ) + (1−
푅푖2
휋2
)퐸푋5∣푦푖,X표푏푠푖 ,푋4 [u푖(휷∣푦푖,X표푏푠푖 , 푋4)]
+(1− 푅푖3
휋3
)퐸푋4∣푦푖,X표푏푠푖 ,푋5 [u푖(휷∣푦푖,X표푏푠푖 , 푋5)]
+(1− 푅푖4
휋4
)퐸X푚푖푠푖 ∣푦푖,X표푏푠푖 [u푖(휷∣푦푖,X표푏푠푖 )]
}
. (5.1)
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Table 5.1: Multi-missingness patterns
(a)
푋표푏푠 푋푚푖푠
푋1 푋2 푋3 푋4 푋5
Study 1
1 1 1 1 1
...
...
...
...
...
1 1 1 1 1
Study 2
1 1 1 1 0
...
...
...
...
...
1 1 1 1 0
Study 3
1 1 1 0 1
...
...
...
...
...
1 1 1 0 1
Study 4
1 1 1 0 0
...
...
...
...
...
1 1 1 0 0
...
...
...
...
...
...
⇒
(b)
푋표푏푠 푋푚푖푠
푋1 푋2 푋3 푋4 푋5
Study 1 1 1 1 1 1
Study 2 1 1 1 1 0
Study 3 1 1 1 0 1
Study 4 1 1 1 0 0
...
...
...
...
...
...
(a). Table of indicators 표푖푙푗 for observed covariate 푙 of subject 푗 in Study 푖. (b). Table of indicators 표푖푙 for
observed covariate 푙 in Study 푖.
73
Suppose the probabilities (휋1, . . . , 휋4) are correctly specified, the first term of uMMWEE(휷)
in (5.1) has expectation equal to 0; that is,
퐸
[
푅푖1
휋1
u푖(휷∣푦푖,X표푏푠푖 ,X푚푖푠푖 )
]
= 퐸
[
퐸푅푖1
(
푅푖1
휋1
)
u푖(휷∣푦푖,X표푏푠푖 ,X푚푖푠푖 )
]
= 퐸
[
1× u푖(휷∣푦푖,X표푏푠푖 ,X푚푖푠푖 )
]
= 0, (5.2)
because the score function has expectation 0.
Now the second term of uMMWEE(휷) in (5.1) has expectation equal to
퐸
[
(1− 푅푖2
휋2
)퐸푋5∣푦푖,X표푏푠푖 ,푋4 [u푖(휷∣푦푖,X표푏푠푖 , 푋4)]
]
= 퐸
[
퐸푅푖2
(
1−푅푖2
휋2
)
퐸푋5∣푦푖,X표푏푠푖 ,푋4 [u푖(휷∣푦푖,X표푏푠푖 , 푋4)]
]
= 퐸
[
0× 퐸푋5∣푦푖,X표푏푠푖 ,푋4 [u푖(휷∣푦푖,X표푏푠푖 , 푋4)]
]
= 0, (5.3)
regardless of whether 퐸푋5∣푦푖,X표푏푠푖 ,푋4 [u푖(휷∣푦푖,X표푏푠푖 , 푋4)] can be correctly calculated or not.
Similarly the third and the fourth term of uMMWEE(휷) equal to 0 too. Thus uMMWEE(휷)
has expectation equal to 0 so 휷ˆMMWEE is asymptotically unbiased. Note that if (휋1, . . . , 휋4)
are correctly specified, uMMWEE(휷ˆ) = 0 will give a consistent estimate of 휷.
In our IPD meta-analysis, an intuitive way to model probabilities (휋1, . . . , 휋4) is
휋푎 =
∑푘
푖=1푅푖푎 × 푛푖
푁
, 푎 = 1, . . . , 4, (5.4)
where 푁 =
∑푘
푖=1 푛푖.
To make the MMWEE method work, two conditions have to be met (double-robustness):
one is to correctly specify the conditional distribution of missing covariates give observed
ones. This can hardly be done because when different studies are pooled, it is not viable
to define a universally applicable conditional distribution which could work for every study.
The other condition is that the missing probabilities (휋1, . . . , 휋4) has to be correctly modeled.
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Since we can assume MCAR in IPD meta-analysis, model (5.4) is a very constructive attempt,
but it is rather intuitive and is in many ways open to questions.
An other problem is that, the score function u푖(휷∣푦푖,X표푏푠푖 ,X푚푖푠푖 ) in Equation (5.1) is easy
to define for simple Cox proportional hazard model but it is extremely difficult to get for
the frailty model. We need to put the frailty parameters into the equation and the score
function may not have a closed form. This adds another huge challenge for the future work.
5.3.2 Integrated IPD and APD meta-analysis
As we discussed in Section (3.1.1), suppose we have a Cox model with treatment variable
푥1푗 and a baseline measure of some important covariate 푥2푗 like this:
ℎ푗(푡∣푥1푗, 푥2푗) = ℎ0(푡) exp(훽1푥1푗 + 훽2푥2푗), (5.5)
and we also consider model 2, where covariate 푥2푗 has been dropped:
ℎ푗(푡∣푥1푗) = ℎ0(푡) exp(훽∗1푥1푗). (5.6)
Gail et al. (1984) [19] provided an approximated estimation of the bias between 훽∗1 and
훽1 as
훿 = 훽∗1 − 훽1 ≈
1
4
휷′2Ω휷2 {푅(훽1)−푅(−훽1)} (5.7)
for vector X2푗, where
푅(휂) = 2휙′(휂)/휙(휂) + 1, (5.8)
휙(휂) = 퐸[퐻0(푡)∣휂]. (5.9)
Thus, when some studies have certain covariates omitted in an IPD meta-analysis, an-
other way to deal with this problem is to get the estimated bias (5.7) from IPD and integrate
this information into an APD meta-analysis. Specifically, treatment effect from study 푖 is
firstly estimated from the Cox proportional hazard model as 훽ˆ1푖 with some covariates omit-
ted. Then 훽˜1푖 = 훽ˆ1푖 + 훿1푖 could be viewed as the adjusted treatment effect from study 푖 and
later are combined using APD meta-analysis techniques to get the pooled treatment effect
estimation.
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APPENDIX A
R PROGRAM FOR APD META-ANALYSIS
library(survival)
library(MASS)
################### Data Generation #####################
Gen.Data = function(size , beta , base.hz, prob.cens , cov.ind)
{
x1 = rbinom(size ,1 ,0.5) # Treatment
x2 = rnorm(size , 0, 10) # Age
x3 = rchisq(size , 3) # Tumor size
x4 = rbinom(size ,1 ,0.6) # ER -positive
x5 = ceiling(rexp(size ,1/3))
x5[rbinom(size ,1 ,0.6) ==0] = 0 # Nodal Status
x = as.matrix(cbind(x1,x2 ,x3 ,x4,x5))
beta = as.matrix(beta)
hr = exp(x%*% beta)
time = rexp(size ,hr*base.hz)
status = rbinom(size ,1,1-prob.cens)
form.full = as.formula(paste ("Surv(time , status)˜", paste("x",
c(1:5) , sep = "", collapse = "+")))
fit.full = summary(coxph(form.full))
form.redu = as.formula(paste ("Surv(time , status)˜", paste("x",
cov.ind , sep = "", collapse = "+")))
fit.redu = summary(coxph(form.redu))
Z = rep(0,6)
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Z[cov.ind] = 1
Z[6] = length(cov.ind)
output = c(fit.full$coef [1,1], fit.full$coef [1,3], fit.
redu$coef [1,1], fit.redu$coef [1,3], Z)
return(output)
}
################### Estimation Functions ####################
theta.IV = function(theta , sigma2)
{
output=sum(ginv(sigma2)%*% theta)/sum(diag(ginv(sigma2)))
return(output)
}
var.IV = function(sigma2)
{
output =1/sum(diag(ginv(sigma2)))
return(output)
}
Q.DL = function(theta , sigma2)
{
output=as.numeric(t(theta -theta.IV(theta ,sigma2))%*% ginv(sigma2
)%*%( theta -theta.IV(theta ,sigma2)))
return(output)
}
tau2.wmm = function(theta , sigma2)
{
weight =1/ diag(sigma2)
output=max(0,(Q.DL(theta , sigma2)-(K-1))/(sum(weight)-sum(
weight ˆ2)/sum(weight)))
return(output)
}
alpha = function(theta , sigma2 , Z)
{
output=ginv(t(Z)%*% ginv(sigma2)%*%Z)%*%(t(Z)%*% ginv(sigma2)%*%
theta)
return(output)
}
var.alpha = function(sigma2 , Z)
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{output=ginv(t(Z)%*% ginv(sigma2)%*%Z)
return(output)
}
D = function(tau2 , Z)
{
part1 = ginv(t(Z)%*% ginv(sigma2+tau2)%*%Z)
part2 = t(Z)%*% ginv(( sigma2+tau2)ˆ2)%*%Z
return(sum(diag(part1 %*% part2)))
}
Q.REG = function(theta , sigma2 , Z)
{
output=as.numeric(t(theta)%*%( ginv(sigma2)-ginv(sigma2)%*%Z%*%
ginv(t(Z)%*% ginv(sigma2)%*%Z)%*%t(Z)%*% ginv(sigma2))%*% theta
)
return(output)
}
tau2.wmm.REG = function(theta , sigma2 , Z)
{
M=diag(x=rep(0,dim(theta)[1]))
output=max(0,(Q.REG(theta ,sigma2 ,Z)-(K-4))/(sum(1/ diag(sigma2))
-D(M,Z)))
return(output)
}
##################### Size varies #########################
meta.size = seq(10, 30, by=3) # Pool of number of studies
size.pool = seq (100 ,500,by=10) # Pool of size for each study
beta=c( -0.2 , -0.1 ,0.1 , -0.15 ,0.7) # Coefficients
iter = length(meta.size)
est.naive = rep(NA ,iter)
est.adv1 = rep(NA ,iter)
est.adv2 = rep(NA ,iter)
est.adv3 = rep(NA ,iter)
se.naive = rep(NA,iter)
se.adv1 = rep(NA ,iter)
se.adv2 = rep(NA ,iter)
se.adv3 = rep(NA ,iter)
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for (k in 1:iter)
{
K = meta.size[k]
ns = 60
est1 = rep(NA,ns)
est2 = rep(NA,ns)
est3 = rep(NA,ns)
est4 = rep(NA,ns)
var1 = rep(NA,ns)
var2 = rep(NA,ns)
var3 = rep(NA,ns)
var4 = rep(NA,ns)
for (j in 1:ns)
{
Data = matrix(NA , nrow=K, ncol =10)
for (i in 1:K)
{
size=sample(size.pool ,1)
base.hz=sample(seq(0.1,0.3, length =100) ,1)
prob.cens=sample(seq(0.1,0.3 , length =100) ,1)
cov.ind = c(1, sample(c(2:5) , sample(c(0:4) ,1),replace=F))
Data[i,] = Gen.Data(size ,beta ,base.hz ,prob.cens ,cov.ind)
}
theta.full = as.matrix(Data [,1])
sigma2.full = diag(x=Data [ ,2]ˆ2)
theta = as.matrix(Data [,3])
sigma2 = diag(x=Data [ ,4]ˆ2)
tau2 = diag(x=rep(0,length(Data [,2])))
V = sigma2+tau2
Z1 = Data [,5:9]
Z2 = Data[,c(5,10)]
score = Z1%*%as.matrix(c(1 ,1.2 ,0.4 ,0.8 ,1.6))
score2 = scoreˆ2
Z3 = cbind(Z2[,1],score)
I5 = as.matrix(c(1,1,1,1,1))
S5 = as.matrix(c(1,5))
V.new = sigma2+diag(x=tau2.wmm(theta ,sigma2),nr=K,nc=K)
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V1.new=sigma2+diag(x=tau2.wmm.REG(theta ,sigma2 ,Z1),nr=K,nc=K)
V2.new=sigma2+diag(x=tau2.wmm.REG(theta ,sigma2 ,Z2),nr=K,nc=K)
V3.new=sigma2+diag(x=tau2.wmm.REG(theta ,sigma2 ,Z3),nr=K,nc=K)
est1[j] = theta.IV(theta ,V.new)
est2[j] = sum(alpha(theta ,V1.new ,Z1))
est3[j] = sum(c(1,5)*alpha(theta , V2.new , Z2))
est4[j] = sum(c(1,5)*alpha(theta , V3.new , Z3))
var1[j] = var.IV(V.new)
var2[j] = t(I5)%*%var.alpha(V1.new ,Z1)%*%I5
var3[j] = t(S5)%*%var.alpha(V2.new ,Z2)%*%S5
var4[j] = t(S5)%*%var.alpha(V3.new ,Z3)%*%S5
}
est.naive[k] = mean(est1)
est.adv1[k] = mean(est2)
est.adv2[k] = mean(est3)
est.adv3[k] = mean(est4)
se.naive[k] = sqrt(mean(var1)+(1+1/ ns)*var(est1))
se.adv1[k] = sqrt(mean(var2)+(1+1/ ns)*var(est2))
se.adv2[k] = sqrt(mean(var3)+(1+1/ ns)*var(est3))
se.adv3[k] = sqrt(mean(var4)+(1+1/ ns)*var(est4))
}
################### Beta Varies #######################
size.pool = seq (100 ,500,by=10) # Pool of size for each study
meta.size = 20
iter = length(seq(-1,-0.1,by=0.1))
beta.pool=cbind(seq(-1,-0.1,by =0.1),rep(-0.1,iter),rep(0.1, iter
),rep(-0.15, iter),rep(0.7, iter)) # Coefficients
est.naive = rep(NA ,iter)
est.adv1 = rep(NA ,iter)
est.adv2 = rep(NA ,iter)
est.adv3 = rep(NA ,iter)
se.naive = rep(NA,iter)
se.adv1 = rep(NA ,iter)
se.adv2 = rep(NA ,iter)
se.adv3 = rep(NA ,iter)
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for (k in 1:iter)
{
K = meta.size
ns = 50
est1 = rep(NA,ns)
est2 = rep(NA,ns)
est3 = rep(NA,ns)
est4 = rep(NA,ns)
var1 = rep(NA,ns)
var2 = rep(NA,ns)
var3 = rep(NA,ns)
var4 = rep(NA,ns)
for (j in 1:ns)
{
Data = matrix(NA , nrow=K, ncol =10)
for (i in 1:K)
{
size=sample(size.pool ,1)
beta = beta.pool[k,]
base.hz=sample(seq(0.1,0.3, length =100) ,1)
prob.cens=sample(seq(0.1,0.3 , length =100) ,1)
cov.ind = c(1, sample(c(2:5) , sample(c(0:4) ,1),replace=F))
Data[i,] = Gen.Data(size ,beta ,base.hz ,prob.cens ,cov.ind)
}
theta = as.matrix(Data [,3])
sigma2 = diag(x=Data [ ,4]ˆ2)
tau2 = diag(x=rep(0,length(Data [,2])))
V = sigma2+tau2
Z1 = Data [,5:9]
Z2 = Data[,c(5,10)]
score = Z1%*%as.matrix(c(1 ,1.2 ,0.4 ,0.8 ,1.6))
Z3 = cbind(Z2[,1],score)
I5 = as.matrix(c(1,1,1,1,1))
S5 = as.matrix(c(1,5))
V.new = sigma2+diag(x=tau2.wmm(theta ,sigma2),nr=K,nc=K)
V1.new=sigma2+diag(x=tau2.wmm.REG(theta ,sigma2 ,Z1),nr=K,nc=K)
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V2.new=sigma2+diag(x=tau2.wmm.REG(theta ,sigma2 ,Z2),nr=K,nc=K)
V3.new=sigma2+diag(x=tau2.wmm.REG(theta ,sigma2 ,Z3),nr=K,nc=K)
est1[j] = theta.IV(theta ,V.new)
est2[j] = sum(alpha(theta ,V1.new ,Z1))
est3[j] = sum(c(1,5)*alpha(theta , V2.new , Z2))
est4[j] = sum(c(1,5)*alpha(theta , V3.new , Z3))
var1[j] = var.IV(V.new)
var2[j] = t(I5)%*%var.alpha(V1.new ,Z1)%*%I5
var3[j] = t(S5)%*%var.alpha(V2.new ,Z2)%*%S5
var4[j] = t(S5)%*%var.alpha(V3.new ,Z3)%*%S5
}
est.naive[k] = mean(est1)
est.adv1[k] = mean(est2)
est.adv2[k] = mean(est3)
est.adv3[k] = mean(est4)
se.naive[k] = sqrt(mean(var1)+(1+1/ ns)*var(est1))
se.adv1[k] = sqrt(mean(var2)+(1+1/ ns)*var(est2))
se.adv2[k] = sqrt(mean(var3)+(1+1/ ns)*var(est3))
se.adv3[k] = sqrt(mean(var4)+(1+1/ ns)*var(est4))
}
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APPENDIX B
R PROGRAM FOR IPD META-ANALYSIS
library(mix)
library(survival)
MI.times = 10 # Number of multiple imputations
F.coef = matrix(NA ,nc=MI.times ,nr=5)
F.var = matrix(NA ,nc=MI.times ,nr=5)
T.coef = matrix(NA ,nc=MI.times ,nr=5)
T.var = matrix(NA ,nc=MI.times ,nr=5)
H.coef = matrix(NA ,nc=MI.times ,nr=5)
H.var = matrix(NA ,nc=MI.times ,nr=5)
for (m in 1:MI.times)
{
k = 20 # Number of studies
index = seq (1:k)
size = sample(seq(100,500,by=1),k)
id = rep(NA,sum(size))
for (i in 1:k)
{
if (i==1) {id[i:size[i]] = rep(index[i],size[i])}
else {id[(sum(size [1:(i-1)])+1):(sum(size [1:(i-1)])+size[i])] =
rep(index[i],size[i])}
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}x1 = rbinom(sum(size) ,1,0.5) # Treatment
x1[x1==0] = 2
x2 = rnorm(sum(size), 0, 10) # Age
x3 = rchisq(sum(size), 3) # Tumor size
x4 = rbinom(sum(size) ,1,0.6) # ER-positive
x4[x4==0] = 2
x5 = ceiling(rexp(sum(size) ,1/3))
x5[rbinom(sum(size) ,1,0.6)==0] = 0 # Nodal Status
x.raw = as.matrix(cbind(x1 ,x4,x2,x3,x5))
beta=as.matrix(c( -0.2 , -0.15 , -0.1 ,0.1 ,0.7))
hr = exp(x.raw%*% beta)
time = rexp(sum(size),hr*0.1)
status = rbinom(sum(size) ,1,1-0.4)
x4.mis = x4
m4 = sample(index ,1) # 1 study has X4 missing
x4.mis[id==m4] = NA
x3.mis = x3
m3 = sample(index ,2) # 2 studies have X3 missing
x3.mis[id==m3[1]|id==m3[2]] = NA
x5.mis = x5
m5 = sample(index ,3) # 3 studies have X5 missing
x5.mis[id==m5[1]|id==m5[2]|id==m5[3]] = NA
x.mis = as.matrix(cbind(x1 ,x4.mis ,x2 ,x3.mis ,x5.mis))
rngseed (123456)
D1 = x.mis[,c(1,2,3)]
s1 = prelim.mix(D1 ,2)
t1 = em.mix(s1 ,showits=F)
nt1 = da.mix(s1,t1 ,steps =500, showits=F)
D1.imp = imp.mix(s1,nt1)
D2 = cbind(D1.imp ,x3.mis)
s2 = prelim.mix(D2 ,2)
t2 = em.mix(s2 ,showits=F)
nt2 = da.mix(s2,t2 ,steps =500, showits=F)
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D2.imp = imp.mix(s2,nt2)
D2.imp[,4][D2.imp[,4]<0] = 0
D3 = cbind(D2.imp ,x5.mis)
s3 = prelim.mix(D3 ,2)
t3 = em.mix(s3 ,showits=F)
nt3 = da.mix(s3,t3 ,steps =500, showits=F)
D3.imp = imp.mix(s3,nt3)
D3.imp[,5][D3.imp[,5]<0] = 0
s = prelim.mix(x.mis ,2)
t = em.mix(s,showits=F)
nt = da.mix(s,t,steps =1000, showits=F)
D.imp = imp.mix(s,nt)
M.F = coxph(Surv(time ,status)˜x1+x4+x2+x3+x5+frailty(id,
distribution ="gamma "))
M.T = coxph(Surv(time ,status)˜D.imp[,1]+D.imp[,2]+D.imp[,3]+D.
imp[,4]+D.imp[,5]+ frailty(id , distribution ="gamma"))
M.H = coxph(Surv(time ,status)˜D3.imp[,1]+D3.imp[,2]+D3.imp[,3]+
D3.imp[,4]+D3.imp[,5]+ frailty(id , distribution ="gamma "))
F.coef[,m] = M.F$coef
F.var[,m] = diag(M.F$var)
T.coef[,m] = M.T$coef
T.var[,m] = diag(M.T$var)
H.coef[,m] = M.H$coef
H.var[,m] = diag(M.H$var)
}
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